Adapted from American College of Endocrinology statement on insulin resistance4
Bold - eligible outcomes
The Agency for Healthcare Research and Quality (AHRQ), through its Evidence-Based Practice Centers (EPCs), sponsors the development of evidence reports and technology assessments to assist public- and private-sector organizations in their efforts to improve the quality of health care in the United States. This report was requested and funded by the Spinal Cord Medicine Consortium, Paralyzed Veterans of America. The reports and assessments provide organizations with comprehensive, science-based information on common, costly medical conditions, and new health care technologies. The EPCs systematically review the relevant scientific literature on topics assigned to them by AHRQ and conduct additional analyses when appropriate prior to developing their reports and assessments.
To bring the broadest range of experts into the development of evidence reports and health technology assessments, AHRQ encourages the EPCs to form partnerships and enter into collaborations with other medical and research organizations. The EPCs work with these partner organizations to ensure that the evidence reports and technology assessments they produce will become building blocks for health care quality improvement projects throughout the Nation. The reports undergo peer review prior to their release.
AHRQ expects that the EPC evidence reports and technology assessments will inform individual health plans, providers, and purchasers as well as the health care system as a whole by providing important information to help improve health care quality.
We welcome written comments on this evidence report. They may be sent to the Task Order Officer named below at: Agency for Healthcare Research and Quality, 540 Gaither Road, Rockville, MD 20850, or by email to epc@ahrq.gov.
Carolyn M. Clancy, M.D.
Director
Agency for Healthcare Research and Quality
J. Paul Thomas
Consortium Coordinator
Spinal Cord Medicine Consortium
Paralyzed Veterans of America
Jean Slutsky, P.A., M.S.P.H.
Director, Center for Outcomes and Evidence
Agency for Healthcare Research and Quality
Beth A. Collins Sharp, R.N., Ph.D.
Director, EPC Program
Michael Handrigan, M.D., FACEP
EPC Program Task Order Officer
Agency for Healthcare Research and Quality
We would like to thank Yuying Chen, M.D., Ph.D., James Fitzsimmons, M.D., David Gater, M.D., Leonard Pogach, M.D., Suparna Rajan, Ph.D., and Thomas E. Stripling for helpful advice throughout the review process, for reviewing the draft, and providing recommendations for revisions and clarifications, and James H. Rimmer, M.D., and William A. Bauman, M.D., for reviewing the draft and providing recommendations for revisions and clarifications. We would also like to thank Maureen Carlyle for assistance with figures and Marilyn Eells for editing and formatting this report.
Objectives: To assess the prevalence of carbohydrate and lipid disorders in adults with chronic spinal cord injury and evaluate their risk contribution to cardiovascular diseases and the potential impact of exercise and pharmacologic and dietary therapies to alter these disorders and reduce cardiovascular disease risk.
Data Sources: MEDLINE® (PubMed®), Cochrane Database and websites of the American Spinal Injury Association, American Paraplegia Society, Paralyzed Veterans of America, Consortium of Spinal Cord Medicine, and WorldCat through August 2007.
Review Methods: English language observational studies addressing prevalence of carbohydrate and lipid disorders were included if they evaluated at least 100 adults with chronic spinal cord injury or a total of 100 subjects if using a control group. Epidemiologic investigations of more than 50 adults with spinal cord injury that were published in English after 1990 and reported cardiovascular morbidity and mortality were abstracted. Intervention studies from 1996-2007 were included regardless of design or size if they assessed exercise, diet, or pharmacologic therapies and reported carbohydrate, lipid, or cardiovascular outcomes.
Results: The quality of evidence regarding the prevalence, impact, and outcomes of carbohydrate and lipid disorders in adults with chronic spinal cord injuries is weak. Evidence is limited by relatively few studies, small sample size, lack of appropriate control groups, failure to adjust for known confounding variables, and variation in reported outcomes. However, the existing evidence does not indicate that adults with spinal cord injuries are at markedly greater risk for carbohydrate and lipid disorders or subsequent cardiovascular morbidity and mortality than able-bodied adults. Body mass index is not reliable for assessing body composition, especially percent body fat, in adults with spinal cord injury. There are no high quality studies evaluating the impact of exercise, diet, or pharmacologic therapies on these disorders.
Conclusions: Evidence does not support using different thresholds to define or treat abnormal lipid and carbohydrate measures or to incorporate other markers to assess risk (e.g., insulin resistance, impaired fasting glucose, or impaired glucose tolerance) for individuals with spinal cord injuries compared to able-bodied adults. Due to physiologic differences between adults with spinal cord injuries and able-bodied individuals, caution may be required when extrapolating findings from studies conducted in able-bodied adults. The role of exercise in individuals with spinal cord injuries represents a unique challenge and requires further exploration into the benefits, harms, and resource implications of broad-based spinal cord injury exercise programs.
Spinal cord injuries (SCI) result in 11,000 hospitalizations of new cases annually in the United States.5, 6 More than 240,000 Americans live with a disability related to SCI and the estimated annual cost averages $9.7 billion.5, 7, 8 Improved quality of care over the last several decades has resulted in a 40 percent decline in mortality during the two years following the injury.9 However, improvement in long-term survival has been smaller. Cardiovascular diseases (CVD) have been reported as the most common cause of death in adults with chronic SCI.2, 10–12 CVD risk factors associated with SCI include behavior (smoking, limited exercise) and metabolic abnormalities (obesity, metabolic syndrome,13–15 and diabetes11). The prevalence of dyslipidemia16, 17 and coronary heart disease has been reported to be higher in adults with SCI compared to the general population.10, 18 The Institute of Medicine recently released two reports that emphasized the role of cardiovascular risk assessment and management in adults with chronic SCI.6, 11 Some evidence suggests that exercise,19 diet,20, 21 and pharmacological therapy22 may reduce diabetes and CVD risk in these individuals. Furthermore, markers or thresholds of carbohydrate and lipid disorders commonly used in adults without SCI may not apply to the population that has sustained SCI. In particular, because adults with SCI lose muscle mass that is replaced with fat mass, traditional measures of obesity (weight or body mass index [BMI]) may not be appropriate.
Accurate estimates of diabetes prevalence and severity in adults with SCI may: 1) be underestimated relative to able-bodied controls because individuals with SCI may not undergo regular testing, 2) have lower levels of high-density lipoprotein (HDL) cholesterol that go unrecognized if providers only assess total cholesterol (TC) levels or base treatment solely on low-density lipoprotein (LDL) cholesterol, or 3) they have earlier evidence of impaired glucose tolerance or altered insulin sensitivity. Existing guidelines do not include routine evaluation of glucose and lipid abnormalities nor do they provide recommendations for threshold definitions of abnormality or target levels for interventions to achieve it.23–25 Furthermore, the prevalence, morbidity, and mortality associated with carbohydrate and lipid disorders may differ in adults with SCI compared to able-bodied individuals.
Effective interventions to treat carbohydrate and lipid disorders and reduce cardiovascular complications in able-bodied individuals include dietary, pharmacologic, and exercise therapies. However, adults with SCI have unique physiologic characteristics that may preclude generalization of evidence from able-bodied individuals to those with SCI. Total daily energy expenditure for adults with SCI is difficult to calculate but likely much lower than for able-bodied individuals, especially among individuals requiring motorized wheelchairs for mobility. Treatment of obesity in SCI remains largely empiric, including guidelines developed for dietary intervention in SCI. Pharmacologic therapies to alter carbohydrate and lipid disorders may have different effectiveness and adverse effects in individuals with SCI compared to able-bodied patients. For example, assessment of hepatic or muscle toxicity in SCI individuals may be difficult using traditional serologic measures developed in able-bodied adults because SCI individuals have reduced muscle mass and potentially altered hepatic metabolism.
Despite the expected benefits of exercise for individuals with SCI, this group also faces unique challenges and risks from exercise that are not experienced by the able-bodied population.8, 26 For one, lack of access to and choices in exercise modes, depending on the neurological impact and level of the injury, form physical barriers to obtaining exercise. Physiological risks of exercise are also a barrier to improved fitness among those with SCI. Depending on the level and completeness of the spinal injury, motor, sensory, and autonomic reflexes may still be intact but no longer under control of the brain. Individuals with SCI also experience various types of autonomic and circulatory dysregulation.26 Risk of stress-related musculoskeletal injury is of concern, given the reliance on a small group of muscles for activities of daily living as well as for any physical conditioning. Fractures, joint dislocation, and overuse injuries are common for individuals with SCI.27
We conducted a systematic review of published evidence to address the following questions:
Question 1a: What proportion of adult patients with chronic posttraumatic spinal cord injuries have been diagnosed with:
Insulin resistance syndrome, metabolic syndrome
Diabetes mellitus Type 2, impaired glucose tolerance
Dyslipidemia
Obesity
Question 1b: Is the prevalence of carbohydrate and lipid disorders higher in the subgroups of patients by age, race, and gender compared to the general population? Does the prevalence of carbohydrate and lipid disorders differ by the time after trauma, the level of trauma, and functional impairment?
Question 2: For people with SCI, what is the evidence on contribution to risk of cardiovascular disease of:
Hyperinsulinemia
Abnormalities in carbohydrate metabolism
Abnormalities in lipid metabolism?
Obesity
This question was refined as:
Question 2: Regarding risk of cardiovascular disease for people with SCI:
What is cardiovascular prevalence and mortality in adults with chronic posttraumatic spinal cord injuries?
Does cardiovascular incidence and mortality in adults with chronic posttraumatic spinal cord injuries differ compared to the general population based on age, race, and gender categories?
What is the strength of the association between cardiovascular incidence and mortality and abnormalities in lipid and glucose metabolism including Type 2 diabetes mellitus after adjustment for possible confounding factors?
Does association vary depending on age, gender, race, the duration after SCI, the level of SCI, and functional impairment?
Question 3: What are the effects on carbohydrate or lipid-related outcomes in adults with SCI of:
Exercise
Dietary and pharmacologic interventions
Studies addressing prevalence of obesity, diabetes, impaired glucose tolerance, insulin resistance, and lipid disorders through August 2007 were included if:
adults had chronic SCI;
the total number of spinal cord subjects was at least 100, or totaling at least 100 subjects if a control group was included (SCI + controls ≥100);
reported prevalence of obesity, diabetes, impaired glucose tolerance, metabolic syndrome or insulin resistance, or lipid disorders or reported mean BMI or lipid levels,
were published in the English language. Abstracts of articles excluded due to small sample size were reviewed to assess for study quality and potential impact.
For Question 2, original epidemiologic investigations of more than 50 adults with chronic SCI and published in English after 1990 were identified in MEDLINE® via PubMed® and the Cochrane library. Websites of the American Spinal Injury Association, American Paraplegia Society, Paralyzed Veterans of America, Consortium of Spinal Cord Medicine, and the catalog WorldCat identified reviews.
For exercise interventions, the Endnote library containing original and review articles (n=2,212) was searched for abstracts that included the words fitness, physical activity, or exercise, resulting in a subset of 303 citations. A MEDLINE® search was conducted of articles written in English and published between 1996 and August 2007. Any identified study was included regardless of design, sample size, or duration if it reported carbohydrate, lipid, or cardiovascular results in adults with chronic SCI.
To assess dietary or pharmacologic interventions for treatment of carbohydrate and lipid metabolism disorders in the SCI population, studies were identified by searching in MEDLINE® through October 2007. Reference lists of included studies or reviews were also searched. Since no randomized trials were identified, nonrandomized studies were eligible. To be included, studies had to:
evaluate adults who had chronic SCI, defined as one year or more since sustaining the injury;
evaluate pharmacologic or dietary interventions;
report carbohydrate and/or lipid-related outcome measures; and
be published in the English language.
Reviewers extracted study and patient characteristics and outcomes onto standardized forms. A second reviewer assessed the findings and disagreements, while rare, were resolved by discussion. Prevalence estimates of obesity, diabetes, lipid disorders, and cardiovascular morbidity and mortality among adults with SCI and, where possible, able-bodied controls, are presented. Findings are reported separately where possible according to age, gender, race, and level/severity of SCI. For Question 3, carbohydrate and lipid outcomes are described according to the exercise, diet, or pharmacologic intervention studied. Due to heterogeneity in populations, interventions, comparator groups, and/or reported outcomes, pooled analyses was generally not conducted.
For Question 1, 23 studies met the inclusion criteria, two studies for insulin resistance/ metabolic syndrome,15, 28 12 studies for diabetes mellitus,3, 15, 28–37 three studies for impaired glucose tolerance,28, 29, 31 seven studies for lipid disorders,16, 17, 21, 31, 38–40 and ten studies for obesity and body composition.28, 31, 36, 38, 40–45 Potentially eligible studies excluded due to small sample size that limited generalizability (n=45, number of SCI individuals in each study ranged from 1–77) were also of low quality and relevance because they were from a single center, not from the United States, lacked controls, and/or did not assess clinically relevant carbohydrate and lipid disorders.
For Question 2, 20 articles of 19 studies met inclusion criteria; most were conducted in the United States.1–3, 30, 32, 34, 36, 37, 39, 46–56 Studies included more than 50,000 patients with SCI. Males (pooled prevalence 86 percent) and Caucasians comprised the majority of individuals. Most used general population controls, were uncontrolled, or did not adjust for known confounding variables including: age, race, gender, smoking status, exercise, or duration of followup. Wide variation existed in the definitions of reported CVD outcomes.
For Question 3a, studies evaluating the following types of exercise were identified: Active Exercise (AE) (seven studies),57–63 Functional Electrical Stimulation exercise (FES) (five studies),64–68 Passive Exercise (PE) (no studies, Self-Reported Physical Activity (six studies),13, 14, 54, 69–71 and Other (one study).72
For Question 3b, only two prospective studies (neither randomized) evaluating dietary and/or lifestyle interventions to reduce lipid levels met inclusion criteria.20, 72
The prevalence of insulin resistance, metabolic syndrome, diabetes mellitus, impaired glucose tolerance, dyslipidemia, and obesity in a population are all highly dependent upon demographics of the population including age, socioeconomic status, and race/ethnicity. The dependence of these conditions on population characteristics makes it difficult to conduct between-study comparisons since population characteristics varied greatly, both between and within studies.
Insulin resistance/metabolic syndrome. There was little data on the prevalence of insulin resistance/metabolic syndrome in adults with SCI. There are no high-quality data to determine if insulin resistance or metabolic syndrome are elevated in adults with SCI compared to similar individuals without SCI because no studies included a non-SCI control or comparison group. Only two studies assessed the prevalence of insulin resistance. The one study that provided results by severity of injury showed increased hyperinsulemia in persons with tetraplegia compared to paraplegia following a glucose challenge.28 The only study assessing metabolic syndrome was small, uncontrolled, and used definitions for specific metabolic disorders likely to increase the estimated prevalence of the disorders and therefore their estimated prevalence of metabolic syndrome. Their definitions are not widely recommended.15, 73
Diabetes mellitus or impaired glucose tolerance (IGT). The prevalence of diabetes appeared higher on average in SCI populations studied compared to the general population. However, there is credible scientific reason to believe that the general population groups selected were not appropriate controls for the studied SCI individuals. For example, lifestyle and comorbidities, irrespective of SCI, could be quite different. Therefore, the extent to which the observed increased prevalence of diabetes is due to a causal relationship between the SCI and the development of subsequent diabetes is not known. Overall, control groups comprised of veterans using Veterans Affairs (VA) medical centers for health care tended to be similar to VA SCI populations in their rate of diabetes. Only when the rate of diabetes in the VA SCI group was compared to the general public did the SCI individuals appear to be at higher risk. Users of the VA health care system have greater comorbidities than either veterans not using the VA health care system or non-VA populations. Therefore, current evidence is insufficient to determine to what extent the higher rate of diabetes is independently attributable to SCI or to other factors that might be higher in adults who subsequently have a SCI than in the general public. There was little evidence suggesting that fasting plasma glucose was elevated in adults with SCI. There was some evidence that adults with SCI may be more likely to meet IGT or diabetes diagnostic criteria following oral glucose tolerance tests (OGTT). However, no studies reported repeated OGTT.
Lipid disorders. There is some evidence that individuals with SCI compared to controls may possess favorably lower average TC (three studies n = 1,427; weighted mean difference (WMD) = -14.3 mg/dL [95 percent CI = -22.2, 6.4]),38–40 LDL cholesterol (two studies, n = 773 WMD = -10.77 [95 percent CI = -16.0, -5.6]),38, 40 and triglyceride levels (two studies n = 773; WMD = -10.0 mg/dL [95 percent CI = -18.3, 1.6]).38, 40 HDL cholesterol was lower in SCI individuals compared to controls (three studies n = 1,427; WMD = -7.6 mg/dL [95 percent CI = -10.6, 4.6]), though confidence intervals were wide and results not statistically significant.38–40
Obesity and body composition. While BMI is unlikely to be an accurate measure of obesity in the SCI population, it is by far the predominant measure reported in research studies of the prevalence of obesity. There is no high quality evidence that obesity defined by BMI is elevated in individuals with SCI compared to appropriately matched controls. There is some evidence that when obesity is measured as percent body fat, individuals with SCI may be at elevated risk. However, the absence of validated measures of body composition in SCI individuals or large studies that include accurate measurements of body fat precludes stronger conclusions regarding the prevalence of obesity and the impact of injury type and duration on obesity.
CVD prevalence among SCI individuals ranged from 1–3 percent in the majority of studies,32, 50, 52, 53, 55 with an increase to 19 percent in older patients and to 14 percent in those 30 or more years after injury.52 The prevalence of cerebrovascular diseases was 1–2 percent3, 39, 53 and coronary heart disease ≤2 percent,32, 39, 53 being increased to 12 percent among members of Paralyzed Veterans of America.37 SCI veterans using VA health care had a higher prevalence of myocardial infarction (14 percent37to 25 percent)48 than SCI civilians (<5 percent in three studies.3, 39, 53 The highest prevalence of 33 percent was reported among veterans who were older than 50 years at the time of injury.48
Mortality from CVDs was more consistent than prevalence across five studies that reported this outcome;1–3, 49, 52 0.849 to 1.52 per 1,000 injured died from diseases of the arteries; 149 -6 percent1 to 10 percent52 died from cardiovascular disease. Mortality was higher in men (5.3 percent) compared to women (1 percent)1 and in older patients, being the highest after 75 years (10 percent).52 Less than 1 percent of SCI patients died from cerebrovascular diseases and stroke,1, 2, 49 with higher mortality in men (0.7 percent) than women (0.2 percent).1 Mortality from ischemic heart disease was <1 percent in two studies2, 3 and 2.5 percent (including 2 percent men) in one European study.1 One long-term followup study of VA users reported a two-fold increase in mortality from 5 years (0.4 percent) to 20 years (0.9 percent) after injury.3 Lung embolus caused death in 0.7 percent of patients with chronic SCI.1
Three studies reported that coronary heart diseases constitute approximately 9 percent among primary causes of death in SCI patients.1–3 The proportion of deaths attributable to all CVDs varied from 18.8 percent for diseases of the heart49 to 24 percent for circulatory system disorders.1 Cardiovascular diseases are among the leading causes of death in patients with chronic SCI1, 49, 52 however, the contribution of age cannot be estimated analyzing crude proportion of aging SCI patients who died from heart diseases. One study of 402 veterans with chronic SCI followed for 55.6 months36 showed that diabetes (relative risk 2.62, 95 percent CI 1.19; 5.77) and heart diseases (relative risk 3.66, 95 percent CI 1.77; 7.78) were significant risk factors for death after adjustment for age.
When compared to able-bodied adults, cardiovascular morbidity in SCI patients did not show significant differences.34, 39 Inconsistent and limited evidence suggested that patients with chronic SCI had lower prevalence of congestive heart failure34 but no differences in the odds of diabetes, myocardial infraction, angina pectoris, or cerebrovascular diseases.34, 39, 55
Diabetes contributed to a higher risk of CVD in veterans with SCI compared to SCI veterans without diabetes. One large study of veterans with SCI, able-bodied veterans, and the general population reported a three times higher rate of diabetes in injured veterans compared to the general population (20 percent vs. 6.7 percent, odds ratio 3.32, 95 percent CI 1.34; 8.26) but similar odds compared to other veterans (21 percent, odds ratio 0.94, 95 percent CI 0.47; 1.87).37 Injured veterans with diabetes had higher adjusted rates of coronary heart disease by 280 percent, myocardial infarction by 270 percent, arterial hypertension by 250 percent, and stroke by 230 percent compared to SCI patients without diabetes.37 Age may modify the association with injury and diabetes. For example, odds of diabetes were higher in injured veterans compared to the general population in all age groups but higher compared to able-bodied veterans in those ages 45–59, 55–59, and older than 70 years.37
Some evidence suggested that neurological functional status may be associated with cardiovascular morbidity.53 Patients with tetraplegia and no functional motor preservation had higher age adjusted odds ratio of cerebrovascular diseases, dysrhythmia, and valvular diseases and lower odds ratio of coronary heart disease compared to paraplegic patients.53 Injured patients with functional motor preservation had higher age adjusted odds of all CVDs, coronary atherosclerosis, dysrhythmia, and valvular disease.53 Some electrocardiogram abnormalities including left bundle branch block, left ventricular hypertrophy with strain, and atrial fibrillation accompanied the higher hazard ratio of death in patients with SCI.34 Furthermore, these abnormalities were associated with a greater risk of dying in injured compared to able-bodied patients.34
Cardiovascular mortality in injured patients was compared to a standardized by age mortality in the general population in three studies.1, 2, 36 Mortality from nonischemic heart diseases (standardized mortality ratio 5.6, 95 percent CI 4.4; 6.8), artery diseases (standardized mortality ratio 4.5 95 percent CI 2.1; 6.9), and lung emboli (standardized mortality ratio 11.4, 95 percent CI 4.2; 24.8) was higher in all injured adults compared to the general population.1 Cardiovascular mortality was lower in those injured after 1972 (standardized mortality ratio 2.4 95 percent CI 1.95; 3.01) compared to those injured from 1953-1971 (7.1, 95 percent CI 2.31; 9.32).1 Patients with complete tetraplegia died from ischemic heart disease (standardized mortality ratio 2.6, 95 percent CI 1.3; 3.9), nonischemic heart diseases (standardized mortality ratio 23.4, 95 percent CI 16.5; 30.3), and cerebrovascular diseases (standardized mortality ratio 5.4, 95 percent CI 1.8; 9) more often than would be expected from the same age able-bodied adults.1, 2, 36
The role of lipid disorders to alter the risk of cardiovascular morbidity and mortality in SCI adults has not been adequately addressed in the published articles. One study concluded that increased blood pressure, elevated blood cholesterol, or smoking could not explain the increased cardiovascular prevalence in SCI patients.39 One study showed that diabetes in SCI patients was associated with an increased risk of coronary heart disease, myocardial infarction, arterial hypertension, high cholesterol, and stroke.37 The relative risk contribution to adults with SCI compared to able-bodied individuals was not reported.
Diabetes mellitus contributed to an increased risk of cardiovascular diseases compared to individuals with SCI but not having a diagnosis of diabetes.37 The relative contribution versus able-bodied individuals is not known. The role of metabolic syndrome had not yet been investigated. Cardiovascular morbidity varied substantially among studies and was highest in injured veterans. Many important confounders might explain such differences beyond the veteran status and many veterans do not receive health care from the VA.74 Indirect comparisons of cardiovascular morbidity in adults with SCI with the general population were inadequate to estimate the relative contribution of metabolic disorders in patients with SCI.
Of the 19 peer reviewed original articles, none were randomized controlled trials (RCTs).13, 14, 54, 57–72 The majority consisted of small case series or uncontrolled cross-sectional surveys using measures of self-reported physical activity. Six studies (n=57) involved active exercise, five (n=32) assessed functional electrical stimulation, and six studies (n=219) evaluated self-reported physical activity. No studies evaluated passive exercise. Carbohydrate related outcomes were reported in ten studies (n=101) and lipid related measures were reported in 13 studies of 292 individuals. Variation in study design, intervention, and reported outcomes precluded quantitative pooling of results or accurate assessment of efficacy. Evidence on effects of exercise on lipid and carbohydrate metabolism disorders is of poor quality and inconclusive in findings. Studies to date have been short in duration, have involved few subjects, and have relied on study designs highly susceptible to error. None assessed glycosylated hemoglobin.
There were no prospective studies that evaluated dietary and/or lifestyle interventions on carbohydrate related outcomes.
Only two poor quality prospective studies evaluated dietary and/or lifestyle interventions to alter lipid levels.20, 72 No studies assessing pharmacologic interventions were identified. The two dietary/lifestyle case-series studies included 238 subjects, overwhelmingly male (87 percent).
One controlled trial compared the effect of a dietary intervention referral compared to no dietary referral20 over a mean of 16 months. Group 1 subjects were older (mean 42.8 versus 35.7, p<0.0001) and had a longer post-injury duration (15.6 versus 11.1 years, p<0.0001) compared to Group 2 subjects. There were reductions in total and LDL cholesterol levels from baseline in Group 1, 234 to 224 (p<0.001) and 159 to 151 (p=0.004), respectively. Levels increased slightly but not significantly in Group 2. There were no significant effects on HDL cholesterol or triglyceride (TG) levels. An uncontrolled study evaluated a weight management program consisting of 12 classes for 12 weeks, primarily led by a registered dietician.72 There were no significant changes in total and LDL cholesterol levels from baseline at weeks 12 and 24. HDL cholesterol was not different at week 24 compared to baseline value.
The present report systematically evaluated published evidence regarding the prevalence of lipid and carbohydrate disorders, CVD, and mortality in adults with chronic posttraumatic SCI. The overall quality of evidence is low. Most studies were retrospective, small, lacked adequate controls, and did not assess or adjust for confounding factors. Outcome measure definitions varied widely. However, limited low quality data suggest that adults with SCI are not at markedly higher risk of carbohydrate and lipid disorders or CVD than age and gender matched able-bodied individuals. Assessment of obesity using BMI is likely to be inaccurate and underestimates body fat in adults with SCI.
The prevalence of insulin resistance, metabolic syndrome, diabetes mellitus, impaired glucose tolerance, dyslipidemia, obesity, and CVD in a population are all highly dependent upon the demographics of the population, including, most importantly, the age distribution, but also socioeconomic status and race/ethnicity. The dependence of these conditions on population characteristics makes it difficult to make between-study comparisons, since the population characteristics range greatly both between and within studies. These factors may explain the wide variation in study prevalence estimates as well as the relative risk compared to different able-bodied control populations.
Some potentially eligible studies (n=45) were excluded due to small sample size (i.e., less than 100 SCI subjects if lacking controls or less than 100 total subjects if including controls). Based on review of published abstracts, the impact of these studies on our overall findings regarding carbohydrate, lipid and body composition disorder prevalence, and subsequent clinical decisionmaking is likely to be small. The number of SCI individuals in the excluded studies ranged from one to 77. Only 17 had control groups. The largest excluded study reporting impaired glucose tolerance and insulin resistance in the United States lacked controls, was comprised of 57 adults from a single center, and was published in 1983. The largest excluded controlled study of lipid disorders was a single center report comprised of 60 young SCI adults (mean age = 28 years) and 28 healthy able-bodied controls matched by age and gender. Serum LDL cholesterol was higher (109 mg/dL vs. 91 mg/dL; p = 0.04) and HDL cholesterol lower (33 mg/dL vs. 44 mg/dL; p =0.004) in SCI adults versus controls. The authors concluded that “serum lipoprotein levels should not be ignored for the followup of patients with spinal cord injury.”75 We agree with their conclusion. Other excluded studies were of even lower quality and relevance to health care in the United States because they were smaller, from a single center, not from the United States, lacked controls, and/or did not assess clinically relevant carbohydrate and lipid disorders.
A previous review76 suggested a high prevalence of CVD in individuals with SCI. However, this report included, but did not differentiate between, highly prevalent self-reported signs and symptoms, such as leg swelling or palpitations56 and less common but more serious conditions or those documented in medical records, such as myocardial infarction (0.28 to 3 percent of SCI patients).3, 53 Several factors may contribute to the prevalence of undiagnosed CVD in SCI individuals, including access and quality of care, asymptomatic angina in patients with diabetes or upper level injury,77, 78 and metabolic syndrome, unstable blood pressure, and cardiac rhythm.79, 80 If screening intensity or criteria to detect/define asymptomatic heart diseases, including coronary heart disease, arrhythmias, and autonomic dysreflexia, differs in SCI compared to able-bodied adults this could bias comparative CVD prevalence estimates.
Prevalence of CVD in aging SCI individuals can be attributable to age rather than injury. Patients differed by the prevalence of risk factors prior to injury and by age at the time of injury. Both could modify the association between SCI and CVD. Indeed, a recently published retrospective analysis found that the presence of cardiovascular disease prior to injury was associated with a 280 percent increase in risk of death.81 For each additional year of age at injury, the relative risk of dying was increased by 8 percent (RR 1.08, 1.06; 1.09).81 Whether the reported increased risk of all CVD in tetraplegic compared to paraplegic individuals can be interpreted as an evidence of higher morbidity53, 76 requires additional studies. Limited evidence suggests that cardiovascular mortality may contribute to approximately 20 percent of all deaths in SCI patients1, 36, 49, 52 and coronary heart disease to 9 percent of all deaths.1–3 There is insufficient evidence to determine whether percentage of deaths due to CVD differs in SCI adults compared to appropriately matched able-bodied individuals. One study suggested that presence of heart diseases was associated with a 3.7 fold increased risk of death in SCI patients compared to SCI patients without CVD, independent of age and other risk factors.52 Limited evidence suggests that the contribution of different forms of heart disease (e.g., ischemic vs. nonischemic coronary heart disease) to overall CVD mortality in SCI patients may differ from the general population. However, proportionate mortality in SCI patients cannot give a valid estimation of mortality rates in this population. Standardized mortality ratios from nonischemic heart diseases, artery diseases, and lung emboli were higher in all injured adults compared to the general population.2 Mortality from lung emboli contributed the most to the overall differences within the total population. However, the inconsistency of results and the multiplicity of outcomes assessed makes it very plausible that these are chance findings.
Whether the independent contribution of diabetes and impaired glucose tolerance on CVD prevalence differs in adults with versus without SCI has not been reported. The association between metabolic control and CVD in adults with SCI remains unclear. Prevalence of retinopathy was not different in SCI users of the VA health care system who were diabetic compared to diabetic able-bodied veterans.37 The impact of lipid disorders on CVD in SCI individuals is not well documented and needs future investigation.
There is no evidence that diagnostic and treatment threshold for carbohydrate and lipid disorders should differ in SCI vs. able-bodied individuals. Assessment of insulin resistance and impaired glucose tolerance are not routinely performed in able-bodied individuals. The effectiveness of screening to improve clinical outcomes by detection of pre-diabetes (impaired fasting glucose or impaired glucose tolerance), insulin resistance, and diabetes in asymptomatic adults has not been demonstrated.73 Use of these tests is limited due to their inconvenience, complexity of testing requirements, costs, and current lack of accuracy. The OGTT is inconvenient and not ordered by most physicians to diagnose diabetes, even among those at risk. Additionally, about one-half with IGT or OGTT would have normal tests if repeated. Similar concerns exist with the criteria used to define impaired fasting glucose. Because the glucose concentration distribution is unimodal, the choice of cutpoints used to designate abnormalities of carbohydrate metabolism is arbitrary. A recent systematic review assessed the comparative effectiveness and safety of oral medications for Type 2 diabetes mellitus. The authors reported that there was no definitive evidence about the comparative effectiveness of oral diabetes agents on all-cause mortality, cardiovascular mortality, or morbidity, peripheral arterial disease, neuropathy, retinopathy, or nephropathy.82 Two more recent meta-analyses of thiazolidinediones have been conducted. Among able-bodied patients with impaired glucose tolerance or Type 2 diabetes (n=14,291), rosiglitazone use for at least 12 months was associated with an increased risk of myocardial infarction and heart failure. There was no difference in increased risk in cardiovascular mortality.83 A review of pioglitazone (n=16,390) showed a significantly lower risk of death, myocardial infarction, or stroke among patients with Type 2 diabetes and inadequate glycemic control. Serious heart failure was increased.84 Existing recommendations to assess cardiovascular risk for able-bodied individuals suggest that all adults should have a complete lipid profile, including HDL and LDL cholesterol levels, as well as family history, smoking status, and gender. The treatment recommendations should be based on that comprehensive risk assessment. Future studies are needed to determine if SCI should be included as an independent risk factor.
The evidence that exercise programs alter carbohydrate and lipid outcomes is of poor quality and inconclusive. Only one study examined the effects of exercise on coronary heart disease outcomes or survival, with no identified associations. There were relatively few consistent findings pertaining to plasma glucose, two-hour post-load glucose, fasting insulin, or two-hour post-load insulin. Similarly, little consistency was reported between studies for HDL cholesterol, TC/HDL, and TG. Results may have indicated some overall post-training benefits for outcomes of TC and LDL cholesterol. While many reported findings are suggested as beneficial in the primary papers as well as past reviews,85 caution in warranted. There was a general lack of quantity, quality, and consistency in methods and outcomes across studies. Reports were based on short-term exercise protocols, often involved carefully recruited hospital- and/or clinic-based patients, and failed to consider implementation or sustainability of exercise interventions in community-based populations. The exercise described in these papers varied considerably from one study to the next. In the cross-sectional surveys, parameters of physical activity were rarely reported.
Exercise and dietary programs among able-bodied individuals have demonstrated a modest improvement in carbohydrate and lipid parameters among selected highly motivated individuals. Translation of these findings to community settings of SCI adults has not been demonstrated and even the effectiveness in the general able-bodied population is unclear. For example, a recent randomized trial evaluated the effects of 22 weeks of aerobic training, resistance training, or both (three times per week) on glycemic control in 251 able-bodied adults with Type 2 diabetes.86 Combined training resulted in a 1 percent absolute reduction in glycated hemoglobin values versus sedentary controls. Reductions due to either resistance or aerobic training alone were about one-half that seen with combination therapy. There was no difference in lipid values, blood pressure, lean body mass, fat mass, or percent body fat of any of the exercise programs versus controls. Adverse events were more common in the exercise group, and 14 percent of those randomized to exercise dropped out.
The available evidence regarding the prevalence, impact, and outcomes of carbohydrate and lipid disorders in adults with chronic SCI is weak. Evidence is limited by relatively small sample size, lack of appropriate control groups, failure to adjust for known confounding variables, and variation in reported outcomes. However, the existing evidence does not indicate that adults with SCI are at markedly greater risk for carbohydrate and lipid disorders or subsequent cardiovascular sequelae than able-bodied adults. The available evidence does not support incorporating SCI status as an independent variable to assess risk of cardiovascular morbidity and mortality or to alter diagnostic/treatment thresholds compared to able-bodied adults. Individuals with SCI may have unique physiologic differences compared to able-bodied individuals. Therefore, caution is advised in attempting to extrapolate findings from studies conducted in able-bodied adults evaluating efficacy and harms of interventions to improve carbohydrate, lipid disorders, and subsequent CVD. Assessment of obesity and body composition by BMI is likely inaccurate and underestimate risks. Alternative methods for assessment in SCI populations are needed. However, unless future high-quality studies suggest otherwise, current evidence supports the conclusion that detection and treatment of carbohydrate and lipid disorders in adults with SCI should be similar to able-bodied individuals.
A major gap in the evidence is the lack of high-quality prospective epidemiologic studies assessing the prevalence and impact of lipid and carbohydrate abnormalities and corresponding CVD complications in SCI individuals, especially compared to appropriately matched able-bodied controls. Future research could include a large prospective multicenter cohort study of adults with SCI. Risk assessment should be started at the time of injury and continued during long-term followup. Prevalence and incidence assessment needs to be objective rather than self reported. Inclusion of baseline and followup physiologic and serologic values (e.g. body composition measures, actual lipid and carbohydrate laboratory values) and standardized outcomes should be made according to well-recognized diagnostic criteria of heart diseases. Expansion of existing cohort studies in the VA, a large non-VA cohort study, and future RCTs that aim to test whether more aggressive screening or treatment within SCI populations actually reduces disease prevalence, morbidity, and mortality could be initiated. Additional information on women is needed.
If prospective cohort studies identify an increased risk in adults with SCI, RCTs will be needed to further extend the information. Techniques for identifying and treating these carbohydrate and lipid disorders and CVDs may need to be modified to meet the specific needs of those with SCI.
The level of injury, neurological impairment, and other known or potential confounders including smoking status, hypertension, family history, race, age, diabetes, infections, socioeconomic status, and quality of health care should be analyzed as possible effect modifiers of the association between well known risk factors and cardiovascular morbidity and mortality.
Consistent, higher quality research on exercise and metabolic and cardiovascular health in SCI patients is needed. Studies examining effectiveness as well as efficacy of exercise interventions are needed. Continued research should be conducted to gain a better idea of the important barriers to exercise experienced by individuals with SCI and to develop novel methods to overcome these barriers. Preliminary studies may also assess which patients are most in need of intervention, the best types of exercise programs and equipment, and how to modify them based on characteristics of the injury. Whether qualitative or quantitative, this preliminary work would not only inform the development of exercise programs but also the research used to evaluate efficacy and effectiveness.
Short-term, intermediate outcomes of exercise, as were typically reported in the current studies, may not be ideal or definitive measurements for this type of research. Studies ideally would focus on long-term clinically relevant outcomes such as prevention of or improvement in diabetes mellitus, coronary heart disease, and mortality. Long-term harms and adherence also need to be assessed. Key variables to be included in future studies are age, race, and gender; comorbid conditions; baseline lipid and carbohydrate related measures; duration, level, and completeness of SCI; functional status; baseline physical activity; exercise program type, frequency, intensity, and duration; and life satisfaction and other important psychosocial variables.
An RCT would provide the best evidence for or against the use of exercise to prevent or control carbohydrate and lipid disorders among those with SCI, though conducting adequately sized studies would be difficult and require cooperative group participation. Further research will be needed to translate any findings of exercise efficacy into effective community-based interventions. Even if efficacy is promising, it will remain to be seen if these interventions are feasible in a community setting and if the interventions, as well as health outcomes, are sustainable over time. Further evidence on how best to motivate individuals to sustain exercise, while preventing and identifying potential harms, will be needed.
RCTs evaluating the potential effectiveness and harms of pharmacologic and dietary interventions to alter CVD risk factors (diabetes, lipid abnormalities and/or obesity) and reduce CVD incidence, morbidity, and mortality may be needed if there is continued concern that results may differ in SCI populations compared to able-bodied adults.
Spinal cord injuries (SCI) result in 11,000 hospitalizations of new cases annually in the United States.5, 6 More than 240,000 Americans live with a disability related to SCI and the estimated annual cost averages $9.7 billion.5, 7, 8 Improved quality of care over the last several decades has resulted in a 40 percent decline in mortality during the two years following the injury.9 However, improvement in long-term survival has been smaller. Cardiovascular diseases (CVD) have been reported as the most common cause of death in adults with chronic SCI.2, 10–12 CVD risk factors associated with SCI include behavior (smoking, limited exercise) and metabolic abnormalities (obesity, metabolic syndrome,13–15 and diabetes11). The prevalence of dyslipidemia16, 17 and coronary heart disease has been reported to be higher in adults with SCI compared to the general population.10, 18 The Institute of Medicine recently released two reports that emphasized the role of cardiovascular risk assessment and management in adults with chronic SCI.6, 11 Some evidence suggests that exercise,19 diet,20, 21 and pharmacological therapy22 may reduce diabetes and cardiovascular disease risk in these individuals. Furthermore, markers or thresholds of carbohydrate and lipid disorders commonly used in adults without SCI may not apply to the population that has sustained SCI. In particular, because adults with SCI lose muscle mass that is replaced with fat mass, traditional measure of obesity (weight or body mass index [BMI]) may not be appropriate.
Accurate estimates of diabetes prevalence and severity in adults with SCI may:
be underestimated relative to able-bodied controls because individuals with SCI may not undergo regular testing,
have lower levels of high-density lipoprotein (HDL) cholesterol that go unrecognized if providers only assess total cholesterol (TC) levels or base treatment solely on low-density lipoprotein (LDL) cholesterol, or
they have earlier evidence of impaired glucose tolerance or altered insulin sensitivity. Existing guidelines do not include routine evaluation of glucose and lipid abnormalities nor do they provide recommendations for threshold definitions of abnormality or target levels for interventions to achieve.23–25 Furthermore, the prevalence, morbidity, and mortality associated with carbohydrate and lipid disorders may differ in adults with SCI compared to able-bodied individuals.
Effective interventions to treat carbohydrate and lipid disorders and reduce cardiovascular complications in able-bodied individuals include dietary, pharmacologic, and exercise therapies. However, adults with SCI have unique physiologic characteristics that may preclude generalization of evidence from able-bodied individuals to those with SCI. Total daily energy expenditure for adults with SCI is difficult to calculate but likely much lower than for able-bodied individuals, especially among individuals requiring motorized wheelchairs for mobility. Treatment of obesity in SCI remains largely empiric, including guidelines developed for dietary intervention in SCI. Pharmacologic therapies to alter carbohydrate and lipid disorders may have different effectiveness and adverse effects in individuals with SCI compared to able-bodied patients. For example, assessment of hepatic or muscle toxicity in SCI individuals may be difficult using traditional serologic measures developed in able-bodied adults because SCI individuals have reduced muscle mass and potentially altered hepatic metabolism.
Despite the expected benefits of exercise for individuals with SCI, this group also faces unique challenges and risks from exercise that are not experienced by the able-bodied population.8, 26 For one, lack of access to and choices in exercise modes, depending on the neurological impact and level of the injury, form physical barriers to obtaining exercise. Physiological risks of exercise are also a barrier to improved fitness among those with SCI. Depending on the level and completeness of the spinal injury, motor, sensory, and autonomic reflexes may still be intact but no longer under control of the brain. Individuals with SCI also experience various types of autonomic and circulatory dysregulation.26 Risk of stress-related musculoskeletal injury is of concern, given the reliance on a small group of muscles for activities of daily living as well as for any physical conditioning. Fractures, joint dislocation, and overuse injuries are common for individuals with SCI.27
In selected highly motivated able-bodied population, exercise, and its resulting improvements in aerobic capacity, appear to modestly improve carbohydrate metabolism, lipid profiles, and general cardiovascular health.7, 87–90 For example, even moderate levels of physical activity, defined as three to six metabolic equivalents (METs) sustained for 30 minutes five to six times per week, may reduce the risk of cardiovascular disease and all-cause mortality.91 Current Centers for Disease Control and Prevention (CDC) and American College of Sports Medicine recommendations for exercise in the able-bodied population include 30 minutes of moderate physical activity, five to six times per week, or 20 minutes of vigorous (greater than six METs) physical activity, three or more times per week.92
However, translation of these findings to community settings of SCI adults has not been demonstrated, and even the effectiveness in the general able-bodied population is unclear. For example, a recent randomized trial evaluated the effects of 22 weeks of aerobic training, resistance training, or both (three times per week) on glycemic control in 251 able-bodied adults with Type 2 diabetes.86 Combined training resulted in a 1 percent absolute reduction in glycated hemoglobin values vs. sedentary controls. Reductions due to either resistance or aerobic training alone were about one-half that seen with combination therapy. There was no difference in lipid values, blood pressure, lean body mass, fat mass, or percent body fat of any of the exercise programs vs. controls. Adverse events were more common in the exercise group and 14 percent of those randomized to exercise dropped out.
Whether this amount of physical activity would produce the same benefits in patients with SCI is unknown. However, it is reasonable to assume that similar metabolic responses to exercise would occur for these individuals. No evidence-based guidelines for exercise in this population currently exist.93 At present, the American College of Sports Medicine's endurance training recommendations for those with SCI are relatively similar to advice directed toward the general population. Generally, the recommended exercise prescription, at least for those with paraplegia, is three to five weekly sessions of 20 to 60 minutes in duration and at an intensity of 50 to 80 percent of the individual's peak heart rate.94 Suggested modes of exercise include arm cranking, wheelchair propulsion, swimming, wheelchair sports, circuit resistance training, electrically-stimulated cycling, and electrically-stimulated walking.
Based on a topic and key questions nominated by the Consortium for Spinal Cord Medicine, we conducted a systematic review of published evidence to address the following questions:
Question 1a: What proportion of adult patients with chronic posttraumatic spinal cord injuries have been diagnosed with:
Insulin resistance syndrome, metabolic syndrome
Diabetes mellitus Type 2, impaired glucose tolerance
Dyslipidemia
Obesity
Question 1b: Is the prevalence of carbohydrate and lipid disorders higher in the subgroups of patients by age, race, and gender compared to the general population? Does the prevalence of carbohydrate and lipid disorders differ by the time after trauma, the level of trauma, and functional impairment?
Question 2: For people with SCI, what is the evidence on contribution to risk of cardiovascular disease of:
Hyperinsulinemia
Abnormalities in carbohydrate metabolism
Abnormalities in lipid metabolism?
Obesity
This question was refined as:
Question 2: Regarding risk of cardiovascular disease for people with SCI:
What is cardiovascular prevalence and mortality in adults with chronic posttraumatic spinal cord injuries?
Does cardiovascular incidence and mortality in adults with chronic posttraumatic spinal cord injuries differ compared to the general population based on age, race, and gender categories?
What is the strength of the association between cardiovascular incidence and mortality and abnormalities in lipid and glucose metabolism including Type 2 diabetes mellitus after adjustment for possible confounding factors?
Does association vary depending on age, gender, race, the duration after SCI, the level of SCI, and functional impairment?
Question 3: What are the effects on carbohydrate or lipid-related outcomes in adults with SCI of:
Exercise
Dietary and pharmacologic interventions
A Technical Expert Panel (TEP) was convened, comprised of individuals with expertise in rehabilitation/physical therapy/neuromuscular aspects of chronic SCI, primary care relevant to patients with chronic SCI, lipid and carbohydrate disorders, dietary intervention, exercise, and pharmacotherapy in patients with chronic SCI. Names of individuals who agreed to participate, their CVs, and disclosure statements were sent to the Agency for Healthcare Research and Quality (AHRQ) for review and approval by the end of January 2007. Those members are identified in Appendix A.
Based on discussions with our partner and TEP members, we developed inclusion and exclusion criteria for study design and size, population, intervention, comparator groups, and outcomes. Question 2 was refined to read:
What is cardiovascular prevalence and mortality in adults with chronic posttraumatic spinal cord injuries?
Does cardiovascular prevalence and mortality in adults with chronic posttraumatic spinal cord injuries differ compared to the general population based on age, race, and gender categories?
What is the strength of the association between cardiovascular prevalence and mortality and abnormalities in lipid and glucose metabolism including Type 2 diabetes mellitus, after adjustment for possible confounding factors?
Does association vary depending on age, gender, race, the duration after SCI, the level of SCI, and functional impairment?
We evaluated, but ultimately did not include, findings from systematic reviews of randomized controlled trials (RCTs) related to behavioral, dietary or pharmacologic interventions as primary prevention of CVD and carbohydrate and lipid disorders in able-bodied adults. The rationale was that little RCT evidence regarding the efficacy and harms of these interventions in SCI individuals existed. It was unlikely that outcomes from these interventions would markedly differ between SCI and able-bodied individuals. Therefore, findings from these intervention studies in able-bodied controls were used to assess baseline lipid and carbohydrate characteristics as well as effectiveness and harms in able-bodied individuals. We also sought to determine whether evidence from these RCTs or current practice guidelines suggested that thresholds for diagnosis or intervention in SCI individuals currently recommended for able-bodied adults should be altered for SCI individuals.
Following the initial conference calls, the Minnesota Evidence-based Practice Center (EPC) conducted a systematic review and meta-analysis (where feasible) of published evidence of the association between lipid and carbohydrate disorders and risk of cardiovascular diseases in adults with chronic SCI. The prevalence of insulin resistance, metabolic syndrome, diabetes mellitus, impaired glucose tolerance, obesity, and abnormalities in lipid metabolism in patients with chronic SCI was estimated from cross-sectional studies that attempted to capture a nationally representative sample of adults with SCI. Observational cohort and case-control studies that tested the hypothesis of the association between carbohydrate and lipid disorders and risk of CVDs in adults with chronic SCI were reviewed. The risk of CVDs among patients with chronic SCI was analyzed. We examined case control and cohort studies to determine if risks of carbohydrate and lipid disorders and CVDs are greater in adults with SCI than in age/gender matched controls without SCI.
The role of different forms of exercise (passive and active, person initiated, and due to electrical stimulation) and diet in the prevention and treatment of carbohydrate and lipid disorders and corresponding sequelae in adults with chronic SCI was evaluated from observational studies and clinical trials. Controlled and randomized trials that examined the effects of exercise, diet, and pharmacological intervention on cardiovascular risk and outcomes in adults with chronic SCI were analyzed. Our preliminary search found few controlled trials of these interventions and only one survey report that assessed their impact on major cardiovascular endpoints, such as morbidity and mortality. Therefore, we estimated the potential impact of early detection and treatment of adults with SCI by evaluating large RCT and systematic reviews of treatments for lipid and carbohydrate disorders in adults without SCI. Our comprehensive work plan covered the assessment and refinement of study questions, proposed literature search and review, inclusion/exclusion criteria, and methods for evaluating the quality of studies and rating the strength of evidence.
Adapted from American College of Endocrinology statement on insulin resistance4
Bold - eligible outcomes
The search strategy is presented in Appendix B. The general approach is described below. Specific items for each question are based on conference calls with our TEP members.
Question 1. A literature search was conducted on Ovid MEDLINE®, using the search term spinal cord injury combined with the following terms: hyperinsulinemia or hyperinsulinism or insulin resistance or Metabolic Syndrome X or metabolic syndrome; diabetes mellitus or glucose intolerance or impaired glucose tolerance; hyperlipidemias or HDL cholesterol or low HDL cholesterol; and obesity. The search was limited to articles published from 1990 to May 2007 or to articles recommended by peer reviewers through October 2007.
Studies were included if:
Adults had chronic SCI, defined as 1 year or more since sustaining the injury;
The total number of spinal cord subjects was at least 100, or totaled at least 100 subjects if a control group was included;
Reported outcomes such as the prevalence of obesity, diabetes, impaired glucose tolerance, metabolic syndrome or insulin resistance, or lipid disorders or reported mean BMI or lipid levels (total cholesterol, HDL cholesterol, LDL cholesterol, or triglycerides);
Were published in the English language. For able-bodied individuals we used nationally representative samples from NHANES that reported on obesity, diabetes and glucose intolerance, and lipid disorders. In particular, we were interested in results provided according to age categories and male gender because nearly 90 percent of reported SCI individuals were male. We also included a single uncontrolled study of 93 SCI adults that assessed insulin resistance and metabolic syndrome because only one other report for insulin resistance and no studies for metabolic syndrome met our predefined eligibility criteria.
Question 2. Original epidemiologic investigations of more than 50 patients with traumatic chronic (>1 year after injury) SCI published in English after 1990 were identified in MEDLINE® via PubMed®. The search of the Cochrane library and the websites including the American Spinal Injury Association, American Paraplegia Society, Paralyzed Veterans of America, Consortium of Spinal Cord Medicine, and the catalog WorldCat identified reviews but not additional original studies.
Question 3a (exercise). The Endnote library containing original and review articles (n=2,212) was searched for abstracts that included the words fitness, physical activity, or exercise, resulting in a subset of 304 citations. In addition, a University of Minnesota medical reference librarian assisted in a MEDLINE® search in response to the question, “What is the role of exercise in the prevention/treatment of carbohydrate and lipid metabolism disorders in people with spinal cord injury or disease?” This search, limited to human studies written in English and published between 1996 and 2007, resulted in 13 original articles as well as one review article. Of these, one relevant original article65 and the review article85 were not previously identified in the Endnote library. The original article was added to the database, for a total of 305 citations.
Question 3b. To identify and evaluate evidence whether pharmacologic or dietary interventions play a role in the prevention and/or treatment of carbohydrate and lipid metabolism disorders in the SCI population, studies were identified by searching in MEDLINE® through May 2007 or by recommendations of peer reviewers through October 2007. Our initial literature search used the same search string utilized for Question 1. In addition, reference lists of relevant studies or reviews were also searched. Since no randomized trials were identified, nonrandomized (controlled or uncontrolled) studies were eligible. To be included, studies had to:
Evaluate adults who had chronic SCI, defined as one year or more since sustaining the injury;
Evaluate pharmacologic or dietary interventions;
Report carbohydrate and/or lipid related outcome measures;
Be published in the English language.
To address question 3b regarding the effectiveness of interventions on carbohydrate and lipid disorders to prevent CVD outcomes and mortality and diabetes in able-bodied adults, we relied on RCTs or systematic reviews of RCTs. Studies were identified using the Cochrane Library and searching MEDLINE® through September 2007. The search was limited to the English language. Included studies must have enrolled or evaluated separately able-bodied adult subjects without pre-existing CVD or Type 2 diabetes and reported clinical outcomes such as mortality, myocardial infarction, stroke, or prevalence of Type 2 diabetes. Studies reporting only improvements in lipid or glucose values were excluded. To limit the scope of the therapeutic interventions, we evaluated primarily clinically proven pharmacologic interventions, with the exception of omega-III fatty acids. Results were assessed and summarized but not formally included in the final report (they are available from the authors upon request).
For Questions 1 and 2 related to prevalence, we extracted the percentage of individuals with a diagnosis of diabetes, impaired glucose tolerance, insulin resistance, lipid abnormality, obesity (including BMI categories), CVD, and mortality according to the definitions provided to the authors. Additionally, we extracted mean carbohydrate, lipid, or BMI values. We pooled values to estimate the mean total, LDL, HDL cholesterol, and triglyceride (TG) values as well as BMI for adults with SCI and displayed these in comparison to a representative sample of U.S. adults from NHANES. Where data were available we used age stratified NHANES values for U.S. males because nearly 90 percent of SCI subjects were male with mean ages between approximately 30 and 60. We used a random-effects model to estimate the weighted mean difference with 95 percent confidence intervals (CI) in lipid values between SCI adults and able-bodied controls.
For Question 2, the results of individual studies were abstracted (see Appendix C for abstraction form) and summarized in evidence tables to analyze the level of evidence, differences in populations and definitions of the outcomes, and the association between risk factors with cardiovascular prevalence and mortality by age and injury status. We analyzed outcomes using the exact definitions from the individual studies. Any combinations were possible only for the same International Classification of Diseases (ICD) codes. Prevalence was calculated as the number of CVD events among the total number of SCI patients in the study; standard error and CI for population prevalence were calculated with Wilson estimate.95 We calculated mortality as a proportion of the patients who died from CVDs during the time of the data collection among the total sample of SCI patients. We could not analyze annual mortality rates because the authors did not report this outcome. We calculated crude odds ratios (OR) of the outcomes when the author reported rates in SCI patients and able-bodied controls.96 Meta-analysis was used to assess the pooled prevalence of CVD with random effects models.97 Assumptions underlying meta-analysis included valid measurements of the outcomes and similarity in study and target populations. Chi squared tests and I squared tests were used to assess heterogeneity in study results.98–100 Calculations were performed using STATA software.101
For Question 3, we extracted and reported the individual study outcome results with tests of significance for SCI patients as reported by authors. Variation in study design, population, intervention, and outcome did not permit pooling.
The strength of the available evidence was rated according to methods of the U.S. Preventive Services Task Force via a three-point scale (high, medium, and low). Confidence in the level of evidence from the review of assessing interventions in able-bodied adults is considered high based on the consistent results from at least two high-quality studies with long-term followup. For all other questions strength is considered low due to serious flaws in study design, inconsistency in findings, and subsequent risk of bias in outcome assessment.
For Question 3, based on the criteria identified above, 304 citations identified through the keyword search were reduced to 19 for use as evidence. Exclusions were based on the following: 38 due to lack of adult, chronic SCI patient population; 18 due to lack of exercise program or measure of self-reported physical activity; 231 due to lack of relevant carbohydrate or lipid related outcome measures. Upon review of citations from the 18 eligible references and one previous review paper, one additional reference was identified and added to the evidence base.69 Thus, results of 19 original studies were synthesized to address this question.
For Question 3b, only two prospective studies in adults with SCI evaluated dietary and/or lifestyle interventions to reduce lipid levels and met inclusion criteria.20, 72
The prevalence of insulin resistance syndrome, metabolic syndrome, diabetes mellitus Type 2, impaired glucose tolerance, dyslipidemia, and obesity in a population are all highly dependent upon demographics of the population, including most importantly the age distribution, but also factors such as socioeconomic status and race/ethnicity. The dependence of these conditions on population characteristics makes it difficult to conduct between-study comparisons, since the population characteristics range greatly both between and within studies. For example, one study might include men and women between the ages of 18 and 70, and within such a study one would expect age and gender stratified proportions of Type 2 diabetes to vary several fold; however, studies of this sort might only present an overall percent that are diabetic. Such an overall value is difficult to interpret and nearly meaningless unless the study has an appropriate control group. In the included evidence tables and figures, results have been presented stratified by age and other key factors (including severity or duration of injury) when such information was reported, but the paucity of consistently stratified results makes pooled estimates nearly impossible. Therefore, we have chosen to focus primarily on the higher quality studies (largest observational reports with control groups).
Currently, there are no high quality studies adequately assessing the prevalence of metabolic syndrome and insulin resistance syndrome in a large population of adults with SCI. There are also no data to assess if the prevalence of either metabolic syndrome or insulin resistance are elevated in adults with SCI compared to similar individuals without SCI. Since metabolic and insulin resistance rates are dependent on age, gender, and race/ethnicity, future studies are needed that are large enough to report rates stratified by these key factors.
The prevalence of diabetes in SCI subjects has been reported in multiple studies (Appendix E Table 1).3, 15, 28–37 Several of these studies have also reported a comparison between SCI individuals and non-SCI subjects (Figure 5
A total of 6,832 persons with SCI and 254,847 controls were included in the reviewed studies, of which the vast majority of all of SCI individuals came from two large Veterans Health Administration (VHA) studies.34, 37 The largest of these studies included a national cross-sectional survey of 3,737 SCI adults who were users of the VA health care system, along with a control group of 6,413 non-SCI VA health-care user control subjects and data from the CDC Behavioral Risk Factor Surveillance System 2003 survey of 221,650 community-dwelling adults.37 This large study found a substantially greater portion of VA SCI individuals self reported that they had diabetes compared to the general population surveyed by the CDC (20 percent versus 7.6 percent, p<0.001). However, overall self-reported prevalence of diabetes in VA users with SCI was similar to the prevalence of diabetes in the non-SCI VA user population (20 percent vs. 21 percent). Another large study also from a VA population found similar rates of diabetes in SCI and non-SCI subjects (11 percent vs. 10 percent, respectively).34 Differences in the overall prevalence of diabetes between these two studies are likely due in part to differences in ascertainment of diabetes status (self-report versus diagnosis in administrative dataset) and differences in the ages of the subjects, with the study reporting higher veteran prevalence of diabetes including older subjects and self-reported surveys. Results from national representative able-bodied populations clearly show that the prevalence of diabetes is highly dependent on method of ascertainment or definition (diagnosed vs. undiagnosed diabetes vs. impaired fasting glucose (Figure 6
The prevalence of diabetes appeared higher on average in SCI populations studied as compared to the general population. However, there is considerable reason to believe that the general population groups used were not appropriate controls for SCI patients. For example, lifestyle and comorbidities, irrespective of SCI, could be quite different. Therefore, the extent to which this increased the prevalence of diabetes is due to a causal relationship between the SCI and the development of subsequent diabetes is not well known. Overall, the VA patient control groups tended to be similar to the VA SCI patient populations in their rate of diabetes, and it was only when the rate of diabetes in the VA SCI patients was compared to the general public that the SCI individuals appeared to be at higher risk. Users of the VA health care system have greater comorbidities than either veterans not actively using the VA health care system or non-VA populations. Therefore, current evidence is insufficient to determine to what extent the higher rate of diabetes is independently attributable to SCI or to other factors that might be higher in adults who subsequently have a SCI than in the general public. While there was not consistent evidence that fasting plasma glucose was substantially different in SCI patients, some evidence suggests that these individuals may be more likely to meet IGT or diabetes mellitus diagnostic criteria following oral glucose tolerance tests. More research is needed to determine whether using the oral glucose tolerance test (OGTT) is more likely to diagnose diabetes in SCI compared to non-SCI patients, and whether individuals diagnosed with diabetes by OGTT benefit from treatment.
The small number of SCI adults with reported lipid values makes it difficult to draw conclusions regarding subcategories of SCI adults with respect to age, sex, race/ethnicity, severity of SCI injury, and duration of SCI injury. The largest study of ethnicity and lipid levels in an SCI population included a total of 600 adults (percentage of whom were male was not reported) of whom 27 percent were White, 47 percent were Hispanic, and 27 percent were African American.17 While this study reported some racial/ethnic differences in lipid levels, there exists almost no evidence regarding whether these possible ethnic differences are unique to SCI individuals. Additionally, this study did not report whether the percentage of individuals who were male differed by ethnicity. The majority of SCI individuals in the studies were men, and even in studies that appeared to contain both men and women, the lipid values were not always reported by sex. In the few studies that did report female-specific lipid values,21, 39, 40 only two reported control groups (n=139 SCI women in controlled studies). Therefore, little evidence exists for whether women with SCI have different lipid levels than able-bodied women. With respect to the type of SCI injury (tetraplegia versus paraplegia, complete versus incomplete), the studies did not report a substantial difference in lipid levels.16, 31, 38, 40
There is some evidence that on average SCI individuals may possess slightly, but likely not clinically meaningfully, reduced total cholesterol, LDL cholesterol, triglycerides (beneficial) and HDL cholesterol (detrimental). The evidence does not support a policy that lipid screening should differ in SCI adults compared to able-bodied adults.
Reports in the general population have consistently shown that the level of obesity is increasing in the United States104 and that this increase in obesity is contributing to an excess in mortality.105 BMI is the primary method used for assessing obesity in population-based studies. However, several alternative methods for assessing obesity exist, including waist circumference, waist-to-hip ratio, percent body fat measured through multiple different techniques, percentage of ideal weight, and others. The use of general population cutpoints for obesity from BMI (>30 kg/m2) have been called into question by the finding that SCI individuals tend to have lower body fat at a given BMI as compared to non-SCI individuals.42 BMI has been and remains the predominant measure of obesity reported in SCI studies.
The prevalence of obesity among SCI populations has been reported in multiple studies,28, 31, 36, 38, 40–45 most of which have included some form of a non-SCI control group.38, 40, 42, 43, 45
Only one of the included studies directly assessed obesity by means other than algorithms based on weight and/or height, primarily recorded as BMI.42 This study of 133 SCI individuals and 100 age-, height-, and ethnicity-matched able-bodied male controls measured percent fat mass using dual energy x-ray absorptiometry (DXA). This study found that total percent lean mass was lower and total percent fat mass higher in SCI individuals for a given level of BMI. The findings from this study combined with the prior studies showing no striking difference in BMI between SCI and able-bodied populations would suggest that future studies should focus less on comparing BMI and should investigate whether other indicators of obesity are more relevant for this population and correspondingly more predictive of future adverse health events. However, it should be noted that while DXA is a reliable measure of body composition, it is also much more difficult and expensive to obtain than BMI.
Several studies have attempted to explore whether differences in injury type (paraplegia versus tetraplegia or complete versus incomplete) or injury duration are correlated with obesity, but as with the overall studies of obesity and SCI, these studies are mostly conducted only with BMI measurements of obesity. Studies that have looked at injury type have tended to find a slightly higher average BMI in adults with paraplegia versus tetraplegia.28, 38, 42–45 However, it is not clear from these studies the extent to which mean BMI is driven by more underweight individuals with tetraplegia or possibly a greater tendency for BMI to underreport obesity in people with tetraplegia compared to people with paraplegia.
Several clinical and research questions remain to be answered, including what is an appropriate definition for obesity in an SCI population? For example, can BMI be used to define obesity? If not, what should be used in its place? If so, can current general population cutpoints for BMI be used or does the cutpoint need to be different (i.e., either specific for SCI in general or even more specific for type of SCI injury)?
There is no high-quality evidence that obesity defined by BMI is elevated in SCI individuals compared to appropriately matched controls. While several authors have reported that BMI might not be an accurate measure of obesity in the SCI population, it is by far the predominant measure used in research studies of the prevalence of obesity. There is some evidence that when obesity is measured as percent body fat, SCI individuals may be at elevated risk; however, the absence of large studies that include accurate measurements of body fat preclude stronger conclusions from being made about the burden of obesity on individuals with SCI and the impact of injury type and duration on the extent of obesity.
| Author | Sample | Patients |
|---|---|---|
| Country | ||
| Cardus, 199246 | 96 | Patients after traumatic SCI who resided in the county area and had to use assistive device for walking. Age: >18 years; Time after injury: >9 months. Controls: 96 nontrained able-bodied men matched by age. |
| USA | ||
| Krum, 199239 | 327 | Patients with SCI and age and sex matched controls from the 1983 Australian Risk Factor Prevalence Study. Gender: 19% female; 25–64 years old; Time after injury: 34% more than 10 years after injury; Injury: 40% with cervical, 35% with lower thoracic, 13% with upper thoracic, and 12% with lumbar levels of injury; ~41% with Frankel Grade A of completeness - complete motor and sensory deficit. |
| Australia | ||
| Whiteneck, 199252 | 834 | Patients with SCI, treated at the British spinal injury centers; Gender: 13% female; Age at time of injury was between 15 and 55 years—15–24 years 42%, 25–34 years 27%, 35–44 years 18%, 45–55 years; median survival time 32 years; Time after injury: >20 years; 412 survivors, Median survival time 32 years; 85% survived at 10 years, 71% at 20 years, 53% at 30 years, and 35% at 40 years after injury. |
| UK | ||
| DeVivo, 19932 | 9,135 | Patients injured between 1973 and 1984 and treated at any of 13 regional SCI care systems. |
| USA | ||
| Imai, 199430 | 244 | Males with SCI identified during the National Livelihood Basic Survey in Japan engaged in light work at special centers, who had medical examination for blood pressure and medical history. Mean age: 49.5 years; Time after injury: average 17.9 years; Injury: 19 patients injured at level C-T5, 24 at T6–T10, 139 at T11-L1, and 13 at L2 or lower. |
| Japan | ||
| Nam, 199447 | 1,027+2,007 | Patients admitted to medical centers with stroke and patients with traumatic SCI (paraplegia or quadriplegia). Population: average age 37.2±16.1 years. |
| USA | ||
| Levi, 199555 | 326 | Patients with traumatic SCI from the Stockholm Spinal Cord Injury Study, residents of the Greater Stockholm area. Control: participants in the Swedish Annual Level-of Living Survey (1,978 interviews). |
| Sweden | ||
| Levi, 199556 | 353 | Patients with traumatic SCI, participants in The Stockholm Spinal Cord Injury Study. Time after injury: 0–4 years after injury 23.97%; 5–17 years after injury 48.76%; 18–44 years after injury 24.52%. |
| Sweden | ||
| McGlinchey-Berroth, 199548 | 534 | Patients with traumatic SCI admitted to the high quality Spinal Cord Injury Service of the VA Medical Center; mean age of 50 years (16–84 years), 23% were at least 65 years of age; Gender: 99% males; Time after injury: 16±13.1 years, 12 hospital admissions since injury. |
| USA | ||
| VA settings | ||
| Time: 1989-1992 | ||
| Imai, 199632(the same population as Imai, 1994)30 | 244, Japan | Males with traumatic SCI at several rehabilitation centers; ages 22 to 69 years (mean 47.6); Time after injury: 17.3 years; Injury: C-T5 level 1%; T6–T10 12%; T11-Ll 69%; L2 8%. Control group (general population) National Livelihood Basic Survey conducted by the Ministry of Health and Welfare in 1989, on 800,000 people in 240,000 households. |
| Hartkopp, 19971 | 888 | Patients (713 men and 175 women) who survived traumatic SCI and were rehabilitated at the Centre for Spinal Cord Injured in Hornbnk, Denmark. Population: median age at the time of injury 27.5 in 1953-1971 and 28.5 in 1972-1990. |
| Denmark | ||
| Rish, 19973 | 230 | Patients with traumatic SCI identified in the Vietnam Head and Spinal Cord Injury Study Registry who survived more then 72 hours, with significant myelopathy; mean age at injury 21.4 years, with previous excellent health (active duty military personnel) mean age at injury 21.4 years; median time after injury 25 years. |
| USA | ||
| VA settings | ||
| Time: 1967-1970 to 1995 | ||
| DeVivo, 199949 | 28,239 | Patients admitted to the model system or to a Shriner's Hospital within 1 year of traumatic SCI who survived at least 24 hours after injury; Gender: 19% female; Race: 67.6% Caucasian, 20.7% African American, 8.1% Hispanic, 3.6% Asian, Native American, or other; Time at injury: 54% of injuries occurred between the ages of 16 and 30 years, and 23% between 31 and 45 years; Injury: 53% cervical, C5–C8 34.5% and C1–C4 18.5% of the population; 53.8% neurologically complete, 27.2% motor functional, 19% sensory sparing or motor nonfunctional; 2.9% were ventilator-dependent. |
| USA | ||
| Groah, 200153 | 834 | Patients alive >20 years after SCI identified in 2 British spinal Injury centers; Mean age 57±10 years; Gender: 14% females; Time after injury: 29±6 years. |
| UK | ||
| Davies, 200254 | 97 | Patients with segmental, nonprogressive traumatic SCI; mean age 47.5±4.5; Gender: 10% females; Age at injury: 31.67±16.4; Time after injury: 15.9±10.1 years; Injury: Quadriplegic 42%; Paraplegic 57%; Undetermined 1%; Complete 33%; Incomplete 64%; Undetermined 3%; Traumatic 87%. |
| Canada | ||
| Prakash, 200234 | 654 | 47,070 patients with at least one ECG obtained in the Palo Alto Veterans Affairs Health Care System; 26,734 able-bodied male veterans and 654 patients with SCI. Mean age: 50±14 years. |
| USA | ||
| VA settings | ||
| Time: 1987-1999 | ||
| Cardenas, 200450 | 8,668 | Patients with traumatic SCI identified in the Model System (hospitalized between acute hospitalization and comprehensive inpatient rehabilitation, admitted to a Model System within 365 days of injury) who reside in the geographic region in which the Model System facility is located; 3,904 patients with 11,047 followup interviews, Gender: 21.4% female; Race: 61.4% White |
| USA | Injury: C1–4 ASIA grades A, B, C: 4.6% | |
C1–4 ASIA grade D: 6.1% | ||
C5–8 ASIA grades A, B, C: 19.1% | ||
C5–8 ASIA grade D: 8.5% | ||
T1-S5 ASIA grades A, B, C: 33.1% | ||
T1-S5 ASIA grade D: 4.2% | ||
| Lavela, 200637 | 5,690 | Veterans with SCI and disorders who use VA health services; Mean age 60 years; Gender: 97% males; Race: White 81%; Time after injury: 24 years; Injury: 52% with paraplegic level injury. Control: 2003 Behavioral Risk Factor Surveillance System survey data for veteran and general population from the Centers for Disease Control and prevention. 6,433 general veteran group and 221,650 general population group. |
| USA | ||
| VA settings | ||
| Time: 2003 | ||
| Lee, 200651 | 168 | Patients with SCI identified in the Spinal Cord Injury Service of the Veterans Affairs Palo Alto Medical Center; Mean age 50.27±12.8 years; Gender: 11% female; Race: 62% White; Time after injury: 19.17±13 years; Injury: 73 (43%) had paraplegia and 95 (56%) tetraplegia. |
| USA | ||
| VA settings | ||
| Garshick, 200536 | 361 | Males with chronic SCI, >20 years of age previously treated by the SCI Service at Veterans Affairs Boston Healthcare System, registered in the National Spinal Cord Injury Association database in Massachusetts, New Hampshire, Vermont, Maine, and Rhode Island (289 veterans and 72 nonveterans); Mean age: 50.6±15.0 years (range 23–87), Race: 93% Caucasian, 5% African American, and 2% other races; Time after injury: 17.5±12.8 years (range 1.0–56.5); Injury: 92% SCI was due to traumatic injury; 37 deaths. |
| USA | ||
| VA settings | ||
| Time: 1994-2000 | ||
| Author | Age, Years | Outcomes | Sample (n) | Prevalence, % |
|---|---|---|---|---|
| Garshick, 200536 | Mean 50.6±15.0 | Hypertension | 361 | 24.4 |
| Groah,* 200153 | Mean 57±10 | Hypertension | 834 | 0.58 |
| Krum, 199239 | Hypertension | 102 | 9 | |
| Lavela, 200637 | Mean 60 | Hypertension | 18,372 | 49 |
| Lee,* 200651 | Mean 50.27±12.8 | Hypertension | 168 | 45.14 |
| Levi, 199555 | Hypertension | 326 | 0 | |
| Prakash,* 200234 | Mean 50±14 | Hypertension | 654 | 7 |
| Rish,* 19973 | Mean at injury 21.4, median time after injury 25 | Hypertension | 230 | 21 |
| Imai, 199632 | Mean 47.6 | Hypertension | 244 | 16.39 |
| Imai, 199632 | Mean 47.6 | Hypotension | 244 | 1.64 |
| Lee,* 200651 | Mean 50.27±12.8 | Prehypertension | 168 | 32.74 |
| Stage 1 hypertension | 168 | 16.07 | ||
| Stage 2 hypertension | 168 | 8.33 | ||
| Krum, 199239 | Range 25–64 | Cerebrovascular accident | 102 | 1 |
| Rish,* 19973 | Mean at injury 21.4, median time after injury 25 | Cerebrovascular accident | 230 | 2 |
| Groah,* 200153 | Mean 57±10 | Cerebrovascular diseases | 834 | 0.05 |
| Angina | 834 | 0.07 | ||
| Krum, 199239 | Range 25–64 | Angina | 102 | 2 |
| Prakash,* 200234 | Mean 50±14 | Coronary artery disease | 654 | 1.7 |
| Rish,* 19973 | Mean at injury 21.4, median time after injury 25 | Coronary artery disease | 230 | 6 |
| Groah,* 200153 | Mean 57±10 | Coronary atherosclerosis | 834 | 0.27 |
| Lavela, 200637 | Mean 60 | Coronary heart disease | 18,372 | 12 |
| Groah,* 200153 | Mean 57±10 | Ischemic heart diseases | 834 | 0.65 |
| Imai, 199632 | Mean 47.6 | Ischemic heart diseases | 244 | 1.64 |
| Groah,* 200153 | Mean 57±10 | Myocardial infarction | 834 | 0.28 |
| Krum, 199239 | Range 25–64 | Myocardial infarction | 102 | 1.9 |
| Lavela, 200637 | Mean 60 | Myocardial infarction | 18,372 | 14 |
| Rish,* 19973 | Mean at injury 21.4, median time after injury 25 | Myocardial infarction | 230 | 3 |
| Levi, 199555 | Cardiac diseases | 326 | 2 | |
| Davies, 200254 | Mean 47.5±4.5 | Cardiovascular morbidity | 140 | 13.4 |
| Groah,* 200153 | Mean 57±10 | Cardiovascular morbidity | 834 | 2.72 |
| Imai, 199632 | Mean 47.6 | Circulatory diseases | 244 | 0.82 |
| Levi, 199555 | Circulatory diseases | 326 | 2 | |
| Prakash,* 200234 | Mean 50 ± 14 | Congestive heart failure | 654 | 1.7 |
| Groah,* 200153 | Mean 57±10 | Dysrhythmia | 834 | 0.43 |
| Left bundle branch block | 834 | 0.02 | ||
| Other CVD | 834 | 0.81 | ||
| Valvular disease | 834 | 0.2 | ||
| Levi, 199556 | Cardiovascular symptoms: ankle-leg edema, chest pain, palpitations | 353 | 58 | |
Outcomes events obtained with ICD codes
Hospitalizations with CVD diagnosis
| Author | Sample (n) | Age at Injury | Prevalence, % |
|---|---|---|---|
| All CVD | |||
| Whiteneck, 1992*52 | 834 | <30 years | 2 |
| 30–39 years | 2.9 | ||
| 40–49 years | 5.2 | ||
| 50–59 years | 8.1 | ||
| 60+ years | 19.3 | ||
| CVD symptoms | |||
| Levi, 199556 | 162 | 21–40 years | 57 |
| 41–77 years | 61 | ||
| Hypertension | |||
| McGlinchey-Berroth, 1995*†48 | 255 | <50 years and <50 years at index submission | 5.09 |
| 162 | <50 years and >50 years at the time of index admission | 25.3 | |
| 93 | Age at injury and index hospital admission >50 years | 33.33 | |
| Myocardial infarction | |||
| McGlinchey-Berroth, 1995†*48 | 255 | <50 years and <5 years at index submission | 5.09 |
| 162 | <50 years of age and >50 years at the time of index admission | 25.3 | |
| 93 | >50 years of age | 33.33 | |
| Years after Injury | |||
| All CVD | |||
| Whiteneck, 1992*52 | 834 | <10 years | 2.9 |
| 10–19 years | 5.4 | ||
| 20–29 years | 10 | ||
| 30+ years | 14.2 | ||
| Cardenas, 2004*†50 | 3,978 | 1 year | 0.73 |
| 1,714 | 10 years | 0.41 | |
| 1,653 | 15 years | 0.79 | |
| 1,251 | 20 years | 0.4 | |
| 2,451 | 5 years | 0.53 | |
| CVD symptoms | |||
| Levi, 199556 | 87 | 0–4 years | 48 |
| 89 | 18–44 years | 72 | |
| 177 | 5–17 years | 55 | |
Outcomes events obtained with ICD codes
Hospitalizations with CVD diagnosis
| Neurological Category | All SCI (N=834) | Tetra ABC (N=99) | Para ABC (N=285) | All D (N=161) | ||||
|---|---|---|---|---|---|---|---|---|
| Number | Rate | Number | Rate | Number | Rate | Number | Rate | |
| All CVD | 458 | 27.2 | 64 | 35.2 | 279 | 29.9 | 115 | 21.2 |
| Coronary heart disease | 109 | 6.5 | 5 | 2.1 | 63 | 6.6 | 41 | 7.4 |
| Myocardial infarction | 47 | 2.8 | 1 | 0.3 | 31 | 3.2 | 15 | 2.6 |
| Angina | 12 | 0.7 | 0 | 4 | 0.4 | 8 | 1.7 | |
| Coronary atherosclerosis | 46 | 2.7 | 3 | 1 | 25 | 2.7 | 18 | 3.1 |
| LBBB | 4 | 0.2 | 1 | 0.3 | 3 | 0.3 | 0 | |
| Hypertension | 98 | 5.8 | 5 | 1.7 | 71 | 7.6 | 22 | 4.5 |
| Cerebrovascular disease | 8 | 0.5 | 4 | 1.5 | 3 | 0.3 | 1 | 0.2 |
| Dysrhythmia | 73 | 4.3 | 20 | 13.1 | 42 | 3.3 | 11 | 1.3 |
| Valvular disease | 34 | 2 | 10 | 5 | 14 | 1.5 | 10 | 1.7 |
| Other CVD | 136 | 8.1 | 20 | 9.2 | 86 | 1.4 | 30 | 1.5 |
Age adjusted rates per 1,000 SCI person years by neurological category
Three studies reported cases of silent ischemia in asymptomatic adults with SCI.10, 106, 107 Tomographic thallium-201 myocardial perfusion imaging detected scintigraphic evidence of ischemia in 3 of 6 patients (50 percent) with tetraplegia and signs of infarction in one patient.106 A simple arm ergometry and radionuclide tomographic image test detected silent scintigraphic evidence of ischemia in 13 SCI patients with paraplegia from 20 tested having normal resting electrocardiograms (65 percent). Since five subjects had ECG evidence of ischemia on exercise testing, eight patients (62 percent) experienced undiagnosed coronary heart disease.107 Latent coronary artery was diagnosed in 12 of 19 subjects with paraplegia (63 percent) using radionuclide myocardial perfusion imaging after upper body ergometry exercise.10 A recently published case control study108 of coronary scanning showed that 91 patients with chronic SCI had the higher mean calcium scores (75±218 versus 28±104, p <0.001) compared to 273 age matched non-SCI controls. The prevalence of coronary artery calcification was greater in the SCI population than the control population (16 percent versus 7 percent, p <0.01).
Pooled analysis detected a significant heterogeneity between studies in estimated prevalence of cardiovascular diseases (data not shown). Therefore, methodological heterogeneity made the pooled estimations not valid. Almost all variations in pooled prevalence of hypertension (14 percent) and myocardial infarction (8 percent) were attributable to heterogeneity between studies. The fact that the summarized prevalence of all CVD events, including coronary heart and non ischemic heart diseases, was less than different forms of CVDs reported in the studies. Such discrepancy can reflect overlap and different definitions and methods to measure outcomes, and, probably, some proportion of undiagnosed cardiac pathology in SCI populations. Three studies reported prevalence in subgroups48, 50, 52 but not in the total sample. Conclusions and decisions based on pooled prevalence cannot be made.
| Author | Sample | Patient Characteristics | Mortality, % Among all SCI Patients |
|---|---|---|---|
| Arterial diseases | |||
| DeVivo, 199949 | 28,239 | All SCI | 0.08 |
| Time: 1973-1998 | |||
| DeVivo, 19932 | 9,135 | All SCI | 0.15 |
| Time: 1973-1985 | Ages 25–54 years | 0.04 | |
| Age >54 years | 0.10 | ||
| Incomplete paraplegia | 0.03 | ||
| Complete paraplegia | 0.03 | ||
| Incomplete quadriplegia | 0.04 | ||
| Complete quadriplegia | 0.04 | ||
| Survival 1–5 years | 0.09 | ||
| Survival >5 years | 0.01 | ||
| Cardiovascular diseases | |||
| Garshick, 200536 | 361 | All SCI | 2.2 |
| Time: 1994-2000 | |||
| Mean age: 50.6±15 | |||
| DeVivo, 199949 | 28,239 | All SCI | 1.03 |
| Time: 1973-1998 | |||
| Hartkopp, 19971 | 888 | All SCI | 6.31 |
| Time: 1954-1992 | Thoracic-lumbar injury/Frankel A-C | 1.58 | |
| Median age at time of injury: 27.5 from 1953-1971 and 28.5 from 1972-1990 | Frankel D | 3.04 | |
| Frankel E | 0.68 | ||
| Cervical lesion | 0.00 | ||
| Thoracic/lumbar lesion | 0.00 | ||
| Men | 5.29 | ||
| Women | 1.01 | ||
| Whiteneck, 199252 | 834 | All patients | 10.07 |
| Time: 1943-1970 | Paraplegia, ABC | 5.76 | |
| Age at time of injury 15–55, 42% 15–24 years, 27% 25–34 years, 18% 35–44 years, 13% 45–55 years; Median survival time 32 years | Quadriplegia, ABC | 0.96 | |
| All D and E | 3.36 | ||
| 15–24 | 0.08 | ||
| 25–34 | 0.07 | ||
| 35–44 | 0.24 | ||
| 45–54 | 0.44 | ||
| 55–64 | 1.33 | ||
| 65–74 | 2.12 | ||
| 75–84 | 10.20 | ||
| Cerebrovascular diseases | |||
| Hartkopp, 19971 | 888 | All patients | 0.90 |
| Time: 1954-1992 | Thoracic-lumbar injury/Frankel A-C | 0.23 | |
| Median age at the time of injury 27.5 in 1953-1971 and 28.5 in 1972-1990 | Frankel D | 0.45 | |
| Frankel E | 0.00 | ||
| Men | 0.68 | ||
| Women | 0.23 | ||
| DeVivo, 19932 | 9,135 | All patients | 0.24 |
| Time:1973-1985 | Ages 25–54 years | 0.15 | |
| Age >54 years | 0.04 | ||
| Incomplete paraplegia | 0.03 | ||
| Complete paraplegia | 0.02 | ||
| Incomplete quadriplegia | 0.09 | ||
| Complete quadriplegia | 0.10 | ||
| Survival 1–5 years | 0.12 | ||
| Survival >5 years | 0.07 | ||
| Ischemic heart disease | |||
| Hartkopp, 19971 | 888 | All patients | 2.48 |
| Time: 1954-1992 | Thoracic-lumbar injury/Frankel A-C | 0.56 | |
| Median age at time of injury: 27.5 from 1953-1971 and 28.5 from 1972-1990 | Frankel D | 1.13 | |
| Frankel E | 0.56 | ||
| Men | 2.14 | ||
| Women | 0.34 | ||
| DeVivo, 19932 | 9,135 | All patients | 0.67 |
| Time: 1973-1985 | Ages 25–54 years | 0.19 | |
| Age >54 years | 0.44 | ||
| Incomplete paraplegia | 0.14 | ||
| Complete paraplegia | 0.12 | ||
| Incomplete quadriplegia | 0.23 | ||
| Complete quadriplegia | 0.18 | ||
| Survival 1–5 years | 0.27 | ||
| Survival >5 years | 0.12 | ||
| Rish, 19973 | 230 | All patients | 0.02 |
| Time: 1954-1992 | Survival 5 years | 0.43 | |
| Mean age at injury 21.4 years, Median time after injury 25 years | Survival 20 years | 0.87 | |
| Survival >20 years | 0.87 | ||
| Lung embolus | |||
| Hartkopp, 19971 | 888 | All patients | 0.68 |
| Time: 1954-1992 | Thoracic-lumbar injury/Frankel A-C | 0.11 | |
| Median age at time of injury 27.5 from 1953-1971 and 28.5 from 1972-1990 | Frankel D | 0.34 | |
| Frankel E | 0.11 | ||
| Men | 0.68 | ||
| Women | 0.00 | ||
| Non ischemic heart disease | |||
| DeVivo, 19932 | 9,135 | All patients | 0.92 |
| Time: 1973-1985 | Ages 25–54 years | 0.31 | |
| Age >54 years | 0.47 | ||
| Incomplete paraplegia | 0.04 | ||
| Complete paraplegia | 0.11 | ||
| Incomplete quadriplegia | 0.28 | ||
| Complete quadriplegia | 0.48 | ||
| Survival 1–5 years | 0.32 | ||
| Survival >5 years | 0.18 | ||
| Stroke | |||
| DeVivo, 199949 | 28,239 | All patients | 0.19 |
| Time: 1973-1998 | |||
| Author | Disease (ICD Codes) | % of all SCI Deaths |
|---|---|---|
| Hartkopp, 19971 | CVD (390–458) | 24.0 |
| Ischemic heart disease (410–414) | 9.0 | |
| DeVivo, 199949 | Heart | 18.8 |
| DeVivo, 19932 | Ischemic heart disease (410–414) | 7.1 |
| Garshick, 200536 | Circulatory system disorder (390–459) | 21.6 |
| Circulatory system disorder (390–459) as contributing cause of death | 18.9 | |
| Rish, 19973 | Myocardial infarction | 8.8 |
| Whiteneck, 199252 | CVD | 23.2 |
| Conditions | Odds Ratio (95% CI) | ||
|---|---|---|---|
| Lavela, 200637VA Settings %; Mean Age 60 Years | Prakash, 200234VA Settings Age 50±14 | Krum, 199239Ages 25–64 | |
| Coronary heart disease | 0.24 (0.13; 0.43) | ||
| Myocardial infarction | 1.00 (0.14; 7.24)† | ||
| Arterial hypertension | 0.16 (0.12; 0.21) | 0.40 (0.17; 0.92) † | |
| High cholesterol | |||
| Stroke | |||
| Diabetes | 3.3 (1.3; 8.3)* | 1.1 (0.88; 1.37) | 3.13 (0.62; 15.89) † |
| Congestive heart failure | 0.24 (0.13; 0.43) | ||
| Angina | 0.67 (0.11; 4.1) † | ||
| Cerebrovascular diseases | 1.00 (0.06; 16.21) † | ||
Adjusted for age, race, marital status, duration of injury, employments status, and educational level
Adjustment for age, matching by gender
Bold - significant association at 95% confidence level
| Diabetes Management or Complications | Prevalence in VA SCI(%) | Prevalence in VA Non SCI(%) | Odds Ratio in VA SCI Compared to the VA Non SCI Population (95% CI) | Prevalence in Non VA General Population (%) | Odds Ratio in VA SCI Compared to Non VA General Population (95% CI) |
|---|---|---|---|---|---|
| Duration of diabetes (>25 years) | 13.55 | 10.94 | 1.27 (0.97; 1.66) | 9.75 | 1.44 (1.16; 1.79) |
| Insulin therapy | 26.03 | 28.51 | 0.88 (0.72; 1.08) | 25.9 | 1.01 (0.85; 1.19) |
| Oral agent | 62.97 | 69.54 | 0.75 (0.62; 0.90) | 66.35 | 0.86 (0.74; 1.01) |
| Insulin + oral agent | 11.25 | 12.82 | 0.86 (0.65; 1.13) | 11.17 | 1.00 (0.79; 1.27) |
| Foot sores with >4 weeks to heal | 41.37 | 17.85 | 3.25 (2.65; 3.98) | 13.12 | 4.68 (4.02; 5.46) |
| Retinopathy | 25.31 | 24.24 | 1.06 (0.86; 1.31) | 22.27 | 1.19 (1.00; 1.41) |
| Diabetes education | 63.04 | 60.16 | 1.13 (0.94; 1.36) | 49.84 | 1.72 (1.47; 2.00) |
Bold - significant association at 95% confidence level
Evidence from one study suggested that neurological functional status may be associated with cardiovascular morbidity (Table 4). Patients with tetraplegia and no functional motor preservation had higher age adjusted odds ratio of cerebrovascular diseases, dysrhythmia, and valvular diseases and lower odds ratio of coronary heart disease compared to paraplegic patients (Figure 18
| ECG Abnormalities | Spinal Cord Injury Hazard Ratio 95% CI | Able-bodied Hazard Ratio 95% CI |
|---|---|---|
| Right bundle branch block | 1.23 (0.4; 4) | 2.21 (1.97; 2.47) |
| Left bundle branch block | 4.24 (1.5; 12) | 1.98 (1.62; 2.42) |
| Intraventricular conduction delay | 1.15 (0.3; 5) | 1.13 (0.99; 1.3) |
| LVH with strain | 3.28 (1.2; 9) | 1.31 (1.14; 1.52) |
| Left atrial abnormality | 0.59 (0.2; 1.9) | 1.55 (1.39; 1.74) |
| Anterior Q wave | 1.44 (0.5; 4.6) | 2 (1.76; 2.28) |
| Inferior Q wave | 0.78 (0.3; 1.8) | 1.32 (1.21; 1.43) |
| Atrial fibrillation | 3.54 (1.2; 11) | 2.02 (1.79; 2.27) |
| Premature ventricular contraction | 0.33 (0.05; 2.5) | 1.51 (1.36; 1.67) |
| Abnormal ST depression | 1 (0.5; 1.9) | 1.9 (1.77; 2.04) |
| Abnormal QT interval | 0.27 (0.1; 18) | 1.91 (1.77; 2.06) |
Bold - significant association at 95% confidence level
| Risk Factors | Death (N) | Standardized Mortality Ratio(95% CI) |
|---|---|---|
| Ischemic heart disease (ICD codes 410–414) | ||
| Age 25–54 years | 17 | 1.4 (0.8; 2.0) |
| Age >54 years | 40 | 1.1 (0.8; 1.4) |
| Incomplete paraplegia | 13 | 1.4 (0.7; 2.1) |
| Complete paraplegia | 11 | 1 (0.4; 1.6) |
| Incomplete quadriplegia | 21 | 1 (0.6; 1.4) |
| Complete quadriplegia | 16 | 2.6 (1.3; 3.9) |
| Survival 1–5 years | 25 | 1.1 (0.7; 1.5) |
| Survival >5 years | 11 | 0.6 (0.2; 1.0) |
| Non ischemic heart disease (ICD codes 420–429) | ||
| Age 25–54 years | 28 | 6.5 (4.1; 10.8) |
| Age >54 years | 43 | 4.2 (3; 5.4) |
| Incomplete paraplegia | 4 | 1.4 (0.4; 2.4) |
| Complete paraplegia | 10 | 2.8 (1.1; 4.5) |
| Incomplete quadriplegia | 26 | 4 (2.5; 5.5) |
| Complete quadriplegia | 44 | 23.4 (16.5; 30.3) |
| Survival 1–5 years | 29 | 4.1 (2.6; 5.6) |
| Survival >5 years | 16 | 3 (1.5; 4.5) |
| Cerebrovascular diseases (ICD codes 430–438) | ||
| Age 25–54 years | 14 | 4.6 (2.2; 7.0) |
| Age >54 years | 4 | 0.4 (0; 0.8) |
| Incomplete paraplegia | 3 | 1.3 (0; 2.8) |
| Complete paraplegia | 2 | 0.8 (0; 1.9) |
| Incomplete quadriplegia | 8 | 1.4 (0.4; 2.4) |
| Complete quadriplegia | 9 | 5.4 (1.8; 9.0) |
| Survival 1–5 years | 11 | 2 (0.8; 3.2) |
| Survival >5years | 6 | 1.3 (0.2; 2.4) |
| Diseases of arteries (ICD codes 440–448) | ||
| Age 25–54 years | 4 | 8.2 (0.2; 16.2) |
| Age >54 years | 9 | 1.2 (0; 3.5) |
| Incomplete paraplegia | 3 | 5.4 (0; 11.5) |
| Complete paraplegia | 3 | 5 (0; 10.6) |
| Incomplete quadriplegia | 4 | 2.7 (0.1; 5.3) |
| Complete quadriplegia | 4 | 9.4 (0.2; 18.6) |
| Survival 1–5 years | 8 | 5.8 (1.8; 9.8) |
| Survival >5 years | 1 | 0.9 (0; 2.7) |
Bold - significant association at 95% confidence level
| Cause of Death | Standardized Mortality Ratio (95% CI) | ||
|---|---|---|---|
| Men | Women | Both Genders | |
| Period of injury 1953-1990 (end of followup: December 31, 1992) | |||
| CVD | 1.2 (0.85; 1.53) | 1 (0.52; 2.14) | 1.2 (0.87; 1.49) |
| Ischemic heart disease | 0.7 (0.41; 1.06) | 1 (0.14; 1.96) | 0.7 (0.42; 1.02) |
| Cerebrovascular disease | 1 (0.35; 2.07) | 1 (0.13; 3.98) | 1 (0.43; 1.94) |
| Lung embolus | 14 (5.25; 31.1) | 11 (4.19; 24.8) | |
| Total | 2.1 (1.79; 2.38) | 2 (1.53; 2.94) | 2.1 (1.83; 2.37) |
| Period of injury 1953-1971 (end of followup: December 31, 1973) | |||
| CVD | 3.2 (1.38; 6.29) | 4 (0.09; 19.5) | 3.2 (1.47; 6.12) |
| Ischemic heart disease | 1.1 (0.13; 3.91) | ||
| Cerebrovascular disease | |||
| Lung embolus | 131 (27.1; 384) | 107 (22.1; 313) | |
| Total | 6.5 (4.66; 8.74) | 12 (5.81; 22.3) | 7.1 (5.31; 9.32) |
| Period of injury 1972-1990 (end of followup: December 31, 1992) | |||
| CVD | 1.3 (0.71; 2.09) | 3 (0.86; 6.16) | 1.5 (0.89; 2.25) |
| Ischemic heart disease | 1.2 (0.58; 2.24) | 1.2 (0.59; 2.13) | |
| Cerebrovascular disease | 4 (0.53; 15.9) | 1.4 (0.28; 3.96) | |
| Total | 2.3 (1.79; 2.90) | 3 (1.91; 5.09) | 2.4 (1.95; 3.01) |
Bold - significant association at 95% confidence level
| Author Sample | Patient Characteristics | Mortality/1,000 SCI | Standardized Mortality Ratios (95% CI) |
|---|---|---|---|
| Artery diseases | |||
| DeVivo, 19932 | Survival >5 years | 0.11 | 0.9 (0; 2.7) |
| N = 9,135 | Age >54 years | 0.99 | 1.2 (0; 3.5) |
| (standardization by age, sex, and race) | Incomplete quadriplegia | 0.44 | 2.7 (0.1; 5.3) |
| All patients | 1.53 | 4.5 (2.1; 6.9) | |
| Complete paraplegia | 0.33 | 5 (0; 10.6) | |
| Incomplete paraplegia | 0.33 | 5.4 (0; 11.5) | |
| Survival 1–5 years | 0.88 | 5.8 (1.8; 9.8) | |
| Age 25–54 years | 0.44 | 8.2 (0.2; 16.2) | |
| Complete quadriplegia | 0.44 | 9.4 (0.2; 18.6) | |
| Garshick, 200536 | All patients | 1.15 (0.13–4.15) | |
| N = 361 | |||
| Cerebrovascular diseases | |||
| DeVivo, 19932 | Age >54 years | 0.44 | 0.4 (0; 0.8) |
| N = 9,135 | Complete paraplegia | 0.22 | 0.8 (0; 1.9) |
| (standardization by age, sex, and race) | Incomplete paraplegia | 0.33 | 1.3 (0; 2.8) |
| Survival >5 years | 0.66 | 1.3 (0.2; 2.4) | |
| Incomplete quadriplegia | 0.88 | 1.4 (0.4; 2.4) | |
| All patients | 2.41 | 1.8 (1; 2.6) | |
| Survival 1–5 years | 1.20 | 2 (0.8; 3.2) | |
| Age 25–54 years | 1.53 | 4.6 (2.2; 7) | |
| Complete quadriplegia | 0.99 | 5.4 (1.8; 9) | |
| Hartkopp, 19971 | Men | 6.76 | 0.95 (0.35; 2.07) |
| N = 888 | All patients | 9.01 | 0.99 (0.43; 1.94) |
| Women | 2.25 | 1.1 (0.13; 3.98) | |
| Cardiovascular diseases | |||
| Hartkopp, 19971 | Cervical lesion | 1.07 (0.72; 1.53) | |
| N = 888 | Women | 10.14 | 1.13 (0.52; 2.14) |
| Men | 52.93 | 1.15 (0.85; 1.53) | |
| All patients | 63.06 | 1.15 (0.87; 1.49) | |
| Thoracic/lumbar lesion | 1.26 (0.82; 1.84) | ||
| Ischemic heart disease | |||
| DeVivo, 19932 | Survival >5 years | 1.20 | 0.6 (0.2; 1) |
| N = 9,135 | |||
| (standardization by age, sex, and race) | |||
| Hartkopp, 19971 | Women | 3.38 | 0.67 (0.14; 1.96) |
| N = 888 | Men | 21.40 | 0.68 (0.41; 1.06) |
| All patients | 24.77 | 0.68 (0.42; 1.02) | |
| DeVivo, 19932 | Complete paraplegia | 1.20 | 1 (0.4; 1.6) |
| N = 9,135 | Incomplete quadriplegia | 2.30 | 1 (0.6; 1.4) |
| (standardization by age, sex, and race) | Age >54 years | 4.38 | 1.1 (0.8; 1.4) |
| Survival 1–5 years | 2.74 | 1.1 (0.7; 1.5) | |
| All patients | 6.68 | 1.3 (1; 1.6) | |
| Age 25–54 years | 1.86 | 1.4 (0.8; 2) | |
| Incomplete paraplegia | 1.42 | 1.4 (0.7; 2.1) | |
| Complete quadriplegia | 1.75 | 2.6 (1.3; 3.9) | |
| Lung embolus | |||
| Hartkopp, 19971 | All patients | 6.76 | 11.4 (4.19; 24.8) |
| N = 888 | Men | 6.76 | 14.3 (5.25; 31.1) |
| Nonischemic heart disease | |||
| DeVivo, 19932 | Incomplete paraplegia | 0.44 | 1.4 (0.4; 2.4) |
| N = 9,135 | Complete paraplegia | 1.09 | 2.8 (1.1; 4.5) |
| Survival >5 years | 1.75 | 3 (1.5; 4.5) | |
| Incomplete quadriplegia | 2.85 | 4 (2.5; 5.5) | |
| Survival 1–5 years | 3.17 | 4.1 (2.6; 5.6) | |
| Age >54 years | 4.71 | 4.2 (3; 5.4) | |
| All SCI | 9.20 | 5.6 (4.4; 6.8) | |
| Age 25–54 years | 3.07 | 6.5 (4.1; 10.8) | |
| Complete quadriplegia | 4.82 | 23.4 (16.5; 30.3) | |
| Diseases of the heart | |||
| Garshick, 200536 | All patients | 0.59 (0.19;1.38) | |
| N = 361 | |||
| Other diseases of the circulatory system | |||
| Garshick, 200536 | All patients | 1.49 (0.31;4.36) | |
| N = 361 | |||
Bold - significant association at 95% confidence level
The role of functional status was reported in one study. Patients with complete tetraplegia died from ischemic heart disease (ICD codes 410–414) (standardized mortality ratio 2.6, 95 percent CI 1.3; 3.9), non ischemic heart diseases (standardized mortality ratio 23.4, 95 percent CI 16.5; 30.3), and cerebrovascular diseases (standardized mortality ratio 5.4, 95 percent CI 1.8; 9) more often than would be expected from the same age able-bodied adults.2
Mortality from nonischemic heart diseases (standardized mortality ratio 5.6, 95 percent CI 4.4; 6.8), artery diseases (standardized mortality ratio 4.5, 95 percent CI 2.1; 6.9), and lung emboli (standardized mortality ratio 11.4, 95 percent CI 4.2; 24.8) was higher in all injured adults compared to the general population.2 Mortality from lung emboli contributed the most to the overall differences within the total population. The role of carbohydrate and lipid disorders (the focus of this review) in nonischemic heart disease and biologic plausibility for this finding is not well known. Therefore, it is possible that these are spurious findings based on multiple comparisons.
Three studies reported that coronary heart disease constitutes approximately 9 percent among primary causes of death in SCI patients.1–3 The proportion of deaths attributable to all CVDs varied from 18.8 percent for diseases of the heart49 to 24 percent for circulatory system disorders.1 Cardiovascular diseases are among the leading causes of death in patients with chronic SCI.1, 49, 52 However, the contribution of age cannot be estimated analyzing crude proportion of aging SCI patients who died from heart diseases. One study of 402 veterans with chronic SCI followed by 55.6 months36 showed that diabetes (relative risk 2.62, 95 percent CI 1.19; 5.77) and heart diseases (relative risk 3.66, 95 percent CI 1.77; 7.78) were significant risk factors for death after adjustment for age.
The role of lipid disorders to increase the risk of cardiovascular morbidity and mortality has not been evaluated in the published articles. The Australian Risk Factor Prevalence Study examined the overall cardiovascular risk in 102 injured patients and age matched control with scores from the MRFIT study (age, diastolic blood pressure, total cholesterol level, cigarettes per day, and sex).39 The injured patients had overall percentile position of risk <50 percent independent of age and years after injury. The authors concluded that increased blood pressure, elevated blood cholesterol, or smoking could not explain cardiovascular prevalence in SCI patients.39 Physical activity, BMI, cigarette use, and alcohol consumption were not associated with increased risk of cardiovascular diseases in the study of 97 injured adults.54 However, the size of this study was too small to rule out clinically meaningful associations. One study showed that diabetes in SCI patients was associated with an increased risk of coronary heart disease, myocardial infarction, arterial hypertension, high cholesterol, and stroke, the well known association in able-bodied adults.37
Published evidence suggested that for people with SCI, diabetes mellitus contributed to an increased risk of CVDs.37 The role of metabolic syndrome and lipid disorders had not yet been investigated. Increased rates of diabetes in SCI compared to able-bodied adults were reported in three articles30, 32, 37 with no differences in the other three.34, 39, 55 The degree of neurological impairment may be associated with cardiovascular mortality in SCI patients with no documented evidence of independent contribution of glucose and lipid disorders. Cardiovascular morbidity varied substantially among studies, being highest in injured veterans. Many important confounders might explain such differences beyond the veteran status, since many veterans do not seek care from the VA.74 The studied veterans are more likely to be poor, without private insurance, have minority status, and/or have a service connected injury.74 Indirect comparisons of cardiovascular morbidity in injured patients with known incidence of CVD in the general population does not permit and accurately estimate the contribution of metabolic disorders in patients with SCI.
Cardiovascular diseases are among the leading causes of death in patients with chronic SCI. However, when compared to able-bodied adults, cardiovascular prevalence in SCI patients did not show significant differences.
Cardiovascular mortality in injured patients was compared to standardized by age mortality in the general population in three studies. Age adjusted mortality from nonischemic heart diseases (standardized mortality ratio 5.6, 95 percent CI 4.4; 6.8), artery diseases (standardized mortality ratio 4.5, 95 percent CI 2.1; 6.9), and lung emboli (standardized mortality ratio 11.4, 95 percent CI 4.2; 24.8) was higher in all injured adults compared to the general population. Cardiovascular mortality was lower in those injured after 1972 (standardized mortality ratio 2.4, 95 percent CI 1.95; 3.01) compared to those injured from 1953-1971 (standardized mortality ratio 7.1, 95 percent CI 2.31; 9.32).
Limited inconsistent evidence suggested higher risk of morbidity and mortality in adults who were older at time of injury. The role of functional status was examined in two studies reporting that patients with tetraplegia had higher odds of having and dying from cerebrovascular diseases. Inconsistent evidence suggested that patients with complete tetraplegia died from ischemic heart disease (standardized mortality ratio 2.6, 95 percent CI 1.3; 3.9) and nonischemic heart diseases (standardized mortality ratio 23.4, 95 percent CI 16.5; 30.3) more often than would be expected from the same age able-bodied adults. However, these findings may be based on chance due to the multiple comparisons and lack of significant associations with other cardiovascular outcomes.
Diabetes contributed to higher risk of CVD in veterans with SCI compared to nondiabetic SCI veterans in one large study. No studies compared risk of CVD among diabetics with SCI to able-bodied diabetics. The role of lipid disorders to increase the risk of cardiovascular morbidity and mortality has not been evaluated in the published articles. One study concluded that increased blood pressure, elevated blood cholesterol, or smoking could not explain increased cardiovascular prevalence in SCI patients.
| Reference | Study Design; Sample Size | Intervention Type | Frequency; Intensity; Duration | Subject Characteristics | Outcomes of Interest | Findings |
|---|---|---|---|---|---|---|
| A. Active exercise | ||||||
| de Groot, 200358 | Case series | Arm crank exercise | 3 sessions/week; | 4 males, 2 females; Age range 19–54 years; | Insulin sensitivity (post-test/pre-test) | Nonsignificant decline in HI group (67%±9%) and nonsignificant improvement in LI group (156%±55%) from baseline |
| n=6 | 60 minutes/session; High-intensity (HI; 70–80% heart rate reserve (HRR)) vs. low-intensity (LI; 40–50% HRR) | Mean duration since injury 116±77 days; | ||||
| Random assignment to high vs. low intensity | 8 weeks of training | 6 paraplegic (C5-L1) | ||||
| Midha, 199960 | Case series | Wheelchair aerobic fitness trainer (WAFT) training program | 2–3 sessions/week; | 11 males, 1 female; | Fasting serum glucose (mg/dL) | No change from pre-training to post-training (86±35 to 85±32) |
| n=12 (Includes 2 nonSCI subjects) | 20–30 minutes, until target heart rate of 90% age-predicted maximum reached; mean intensity 177 watts | Age range 22–58; | ||||
| 10 weeks of training | Duration since injury range 4–29 years; | |||||
| 3 quadriplegic; | ||||||
| 7 paraplegic; | ||||||
| 1 stroke; | ||||||
| 1 amputee | ||||||
| Phillips, 200462 | Case series | Body-weight supported treadmill training program | 68 sessions (2.8±0.2 sessions/week); | 8 males, 1 female; |
|
|
| n=9 | Velocity and % weight supported varied for each participant; | Mean age 31±3 years; | ||||
| 6.0±0.3 months of training | Mean duration since injury 8.1 years; | |||||
| 9 incomplete (C4-T12) | ||||||
| B. Functional electrical stimulation exercise | ||||||
| Chilibeck, 199964 | Case series | Electrically stimulated leg cycling program | 3 sessions/week; | 4 males, 1 female; |
|
|
| n=5 | 30 minutes/session; | Age range 31–50 years; | ||||
| Power 6.0 watts, increased as possible each session; | Duration since injury range 3–25 years; | |||||
| 50 revolutions/minute; | 5 complete (C5-T8) | |||||
| 8 weeks of training | ||||||
| Hjeltnes, 199865 | Case series | Electrically stimulated leg cycling program | 7 sessions/week; | 5 males, 0 females; |
|
|
| n=5 | 30 minutes/session or until fatigued; | Mean age 35±3 years; | ||||
| Power 6.0 watts, increased by 6.1 watts each session; | Mean duration since injury 10.2±3.4 years; | |||||
| 50 revolutions/minute; | 5 tetraplegic; | |||||
| 8 weeks of training | 5 complete (C5–C7) | |||||
| Jeon, 200266 | Case series | Electrically stimulated leg cycling program | 3 sessions/week; | 5 males, 2 females; |
|
|
| n=7 | 30 minutes/session; | Age range 30–53 years; | ||||
| 50–60% VO2 maximum; | Duration since injury range 3–40 years; | |||||
| 8 weeks of training | 3 tetraplegic | |||||
| 4 paraplegic | ||||||
| 7 complete (C5-T10) | ||||||
| Mahoney, 200567 | Case series | Resistance exercise training program | 2 sessions/week; | 5 males, 0 females; |
|
|
| n=5 | 4 sets of 10 unilateral, dynamic knee extensions; | Mean age 35.6±4.9 years; | ||||
| 12 weeks of training | Mean duration since injury 13.4±6.5 years; | |||||
| 5 complete (C5-T9) | ||||||
| Mohr, 200168 | Case series | Exercise program with functional electrical stimulation cycling ergometer | 3 sessions/week; | 8 males, 2 females; |
|
|
| n=10 | 30 minutes/session; | Mean age 35±2 years; | ||||
| 50 revolutions/minute; | Mean duration since injury 12±2; | |||||
| 1 year of training | 6 tetraplegic (C6); | |||||
| 4 paraplegic (T4) | ||||||
| C. Passive exercise | ||||||
| No eligible studies | ||||||
| D. Self-reported physical activity | ||||||
| Jones, 200414 | Cross-sectional case-control survey | NA | NA | 20 males, 0 females; |
|
|
| n=20 | Assessed physical activity levels (minutes/week) and metabolic variables | Age range 16–52 years; | ||||
| Mean duration since injury 10.3±1.8 years; | ||||||
| 11 tetraplegic (C4–C7); | ||||||
| 9 paraplegic (T5-L5) | ||||||
| Manns, 200513 | Cross-sectional survey | NA | NA | 22 males, 0 females; |
|
|
| n=22 | Assessed physical activity levels and metabolic variables | Mean age 39±-9 years; | ||||
| Mean duration since injury 17±9 years; | ||||||
| 22 paraplegic (T2-L2); | ||||||
| 22 complete | ||||||
| E. Other | ||||||
| No eligible studies | ||||||
| Reference | Study Design; Sample Size | Intervention Type | Frequency; Intensity; Duration | Subject Characteristics | Outcomes of Interest | Findings |
|---|---|---|---|---|---|---|
| A. Active exercise | ||||||
| Durán, 200157 | Case series | Training program including mobility, strength, coordination, aerobic resistance, and relaxation activities | 3 sessions/week; | 12 males, 1 female; |
|
|
| n=13 | 120 minutes/session; | Mean age 26.3±8.3 years; | ||||
| Target HR 40%–80% of maximal HR; | Duration since injury range 2–120 months; | |||||
| 16 weeks of training | 13 paraplegic | |||||
| 4 T6 or higher; | ||||||
| 9 T6 or lower | ||||||
| de Groot, 200358 | Case series | Arm crank exercise program | 3 sessions/week; | 4 males, 2 females; |
|
|
| n=6 | 60 minutes/session; | Age range 19–54 years; | ||||
| Random assignment to high vs. low intensity | High intensity (HI; 70–80% heart rate reserve) vs. low intensity (LI; 40–50% HRR); | Mean duration since injury 116±77 days; | ||||
| 8 weeks of training | 6 paraplegic (C5-L1) | |||||
| El-Sayed, 200559 | Controlled case series | Arm crank exercise program | 3 sessions/week; | 5 paraplegic (SCI); |
|
|
| n=12 | 30 minutes/session; | 7 able-bodied (AB); | ||||
| 60–65% VO2 peak; | Mean age 32±1.6 years for AB; | |||||
| 12 weeks of training | Mean age 31±2.9 years for SCI | |||||
| Midha, 199960 | Case series | WAFT training program | 2–3 sessions/week; | 11 males, 1 female; |
|
|
| n=12 (includes 2 non-SCI subjects) | 20–30 minutes, until target heart rate of 90% age-predicted maximum reached; | Age range 22–58; | ||||
| Mean intensity 177 watts; | Duration since injury range 4–29 years; | |||||
| 10 weeks of training | 3 tetraplegic; | |||||
| 7 paraplegic; | ||||||
| 1 stroke; | ||||||
| 1 amputee | ||||||
| Nash, 200161 | Case series | Arm crank exercise program, with focus on resistance and endurance | 3 sessions/week; | 5 males, 0 females; |
|
|
| n=5 | 45 minutes/session; | Age range 34–43 years; | ||||
| Power output 400 kpm + 100 kpm every 3 minutes until peak VO2 maximum; | Mean duration since injury 4.8±1.4 years; | |||||
| 3 months of training | 6 paraplegic; | |||||
| 5 complete (T6-L1) | ||||||
| Stewart, 200463 | Case series | Body-weight supported treadmill training program | 68 sessions (2.8±0.2 sessions/week); | 8 males, 1 female; |
|
|
| n=9 | Velocity and % weight support varied for each participant; | Mean age 31±3 years; | ||||
| 6.0±0.3 months of training | Mean duration since injury 8.1 years; | |||||
| 9 incomplete (C4-T12) | ||||||
| B. Functional electrical stimulation exercise | ||||||
| No eligible studies | ||||||
| C. Passive exercise | ||||||
| No eligible studies | ||||||
| D. Self-reported physical activity | ||||||
| Dallmeijer, 199970 | Case-series survey | NA | NA | 15 males, 4 females; |
|
|
| n=19 | Assessed risk profiles and sport activity (hours/week) at t1 (during rehab) and t2 (1 year post-discharge) | Mean age 40.7±14.7 years; | ||||
| Mean duration since injury 760±169 days; | ||||||
| 9 tetraplegic; | ||||||
| 10 paraplegic | ||||||
| Dallmeijer, 199769 | Cross-sectional survey | NA | NA | 24 males, 0 females |
|
|
| n=24 | Compared lipid levels between physically active (1.5–6.0 hours/week) and sedentary SCI patients | 11 physically active | ||||
| 13 sedentary | ||||||
| 24 tetraplegic | ||||||
| 4 incomplete | ||||||
| 20 complete | ||||||
| Davies, 200254 | Cross-sectional survey | NA | NA | 87 males, 10 females; | Cardiovascular morbidity | No association with physical activity |
| n=97 | Assessed physical activity as determinant of cardiovascular morbidity (both measurements made with valid and reliable scale) | Mean age 47.5±4.5 years; | ||||
| Mean duration since injury 15.9±10.1 years; | ||||||
| 41 tetraplegic | ||||||
| 55 paraplegic | ||||||
| 1 undetermined | ||||||
| 32 complete | ||||||
| 62 incomplete | ||||||
| 3 undetermined | ||||||
| Janssen, 199771 | Cross-sectional survey | NA | NA | 37 males, 0 females; |
|
|
| n=37 | Assessed sport activity (hours/week) as determinant of lipid profiles | Age range 19–71 years; | ||||
| Duration since injury range 4–33 years; | ||||||
| 8 tetraplegic | ||||||
| 29 paraplegic | ||||||
| 23 complete | ||||||
| Jones, 200414 | Cross-sectional case-control survey | NA | NA | 20 males, 0 females; |
|
|
| n=20 | Assessed physical activity levels (minutes/week) and metabolic variables | Age range 16–52 years; | ||||
| Mean duration since injury 10.3±1.8 years; | ||||||
| 11 tetraplegic (C4–C7) | ||||||
| 9 paraplegic (T5-L5) | ||||||
| Manns, 200513 | Cross-sectional survey | NA | NA | 22 males, 0 females; |
|
|
| n=22 | Assessed physical activity levels and metabolic variables | Age range 39±9 years; | ||||
| Mean duration since injury 17±9 years; | ||||||
| 22 paraplegic (T2-L2); | ||||||
| 22 complete | ||||||
| E. Other | ||||||
| Chen, 200672 | Case series | NA | Followup testing at 12 weeks and 24 weeks | 9 males, 7 females; |
|
|
| n=16 | Participation in weight management program where exercise behavior was taught | Age range 21–66 years; | (-1.8±22.1, p = .76) | |||
| Mean duration since injury 17.5 years | ||||||
| 15 SCI | ||||||
| 1 spinal cord illness | ||||||
Active Exercise (AE): n=six studies of 57 individuals (40 males, five females, 12 unreported; 36 paraplegic, three tetraplegic, nine unclassified and nine other) (8–24 weeks exercise duration).57–63
Functional Electrical Stimulation Exercise (FES): n=five studies of 32 individuals (27 males, five females; eight paraplegic, 14 tetraplegic and ten unclassified) (8–52 weeks exercise duration)64–68
Passive Exercise (PE): n=0 studies
Self-Reported Physical Activity: n=six studies of 215 individuals (205 males, 14 females; 125 paraplegic, 93 tetraplegic, one unclassified) (no report of duration)13, 14, 54, 69–71
Other: n=one study (nine males, seven females) (no report of duration)72
The overall quality, quantity, and consistency of evidence for exercise as an intervention for carbohydrate disorders is poor. Study characteristics ranged from a case series using pre-post assessment of outcomes for six individuals randomly assigned to eight weeks of high- versus low-intensity arm crank exercise58 to a cross-sectional survey of 22 individuals who provided self-assessed physical activity levels and metabolic variables.13 The intervention type, frequency, intensity, and duration varied considerably across studies. Most involved several sessions of supervised exercise per week with a study duration ranging from eight weeks to one year. SCI level and severity, and duration since injury, varied across studies. More than 90 percent of subjects were men. One study was a survey of self-reported exercise or physical activity and assessed the impact of the respondent's activity on major cardiovascular endpoints.54 Three studies examined the effects of active exercise (AE),58, 60, 62 while five examined the effects of FES exercise,64–68 on carbohydrate related measures. Two survey studies assessed the association between self-reported physical activity and these measures.13, 14 The most commonly assessed measures were fasting plasma glucose and oral glucose tolerance tests, measuring post-oral load levels of glucose and insulin. None assessed glycosylated hemoglobin.
There is mixed, low-quality evidence that a program of exercise improves carbohydrate-related measures. Of the five studies that measured fasting plasma glucose only one showed a statistically significant difference. Two (one AE; one FES) found no differences before and after intervention,60, 65 while one FES study found a nonstatistically significant trend for reduction.67 Two surveys identified inverse correlations (r = -.53 and -.40 respectively) between self-reported physical activity and plasma glucose; one was statistically significant13 while the other was not.14 Measures of two-hour post-load glucose were mixed. One FES study found a significant (p = .014), 13 percent post-training reduction in glucose levels, averaged across participants,66 while another FES study showed no change.68 Both survey studies of self-reported physical activity identified inverse correlations (r = -.59 and -.34 respectively) with two-hour post-load glucose; the prior was statistically significant (p <0.01)14 while the latter was not.13 Impaired glucose tolerance and clearing were also reported. One AE study showed a statistically significant post-training 15 percent average reduction in area under the curve after glucose load,62 and one FES study found a significant 33 percent average increase in glucose disposal.65
Measures of insulin levels were no more uniform than for glucose. Some studies assessed fasting insulin levels, while others assessed insulin levels after a standard glucose load or insulin area under the curve. One possible consistency in these studies is the lack of change in fasting plasma insulin levels after training. Two FES studies found no difference in fasting plasma insulin,65, 67 while one identified decreased levels that were not significant.64 One survey study showed no correlation between self-reported physical activity and insulin;14 the other survey study did identify an inverse correlation (r = -.40), but it was not statistically significant (p >0.05).13 Plasma insulin concentrations after oral glucose load were also inconsistent. One FES study identified a nonsignificant 26 percent average reduction in two-hour post-load levels,66 while another FES study found no change.68 Similarly, one survey study identified a statistically significant inverse correlation (r = -.79. p <0.01) between self-reported physical activity and post-load insulin,14 while the other found no correlation.13 One AE study identified a significant 33 percent average reduction in area under the curve for plasma insulin concentrations after glucose load.62 To further complicate any possible conclusions, the AE study comparing two programs of exercise (low intensity vs. high intensity)58 found insulin sensitivity to be decreased by an average of 33 percent for those assigned the low intensity intervention, but increased an average of 56 percent for those in the high intensity intervention.
The quality, quantity, and consistency of evidence for studies reporting lipid related measures is also poor. Study designs were primarily reports of case series and cross-sectional surveys, with intervention type, frequency, intensity, and duration varied across studies. Nearly 90 percent of subjects were men, thus limiting extrapolation of findings in women. Six studies examined the effects of AE on lipid related measures.57–61, 63 No eligible studies examined FES exercise. There were six survey studies that assessed the association between self-reported physical activity and lipid measures.13, 14, 54, 69–71 One of these examined the association between physical activity and cardiovascular morbidity.54 One study, categorized as “other,” examined the effects of a weight management training program, including curriculum on exercise, on lipid outcomes.72 The most common lipid related measures were TC, HDL-C, LDL-C, the ratio of TC to HDL-C (TC/HDL-C), and TG.
Evidence may point to improved levels of TC after a training intervention, or with self-reported physical activity. Among the studies examining effects of AE interventions, two identified statistically significant reductions in TC levels (on average, 8 percent and 10 percent less than pre-training);60, 63 these involved training programs with a body-weight supported treadmill63 or a wheelchair aerobic fitness trainer.60 One study found a nonsignificant 9 percent average decrease,61 while two showed no changes;58, 59 all three of these studies involved arm crank exercise. Three survey studies examined self-reported exercise and TC levels.69–71 While one found no difference in TC levels between those who were physically active and those who were sedentary,69 two others identified significant inverse correlations (r = -.35 and -.33, p = 0.008 and p <0.05, respectively). The study examining the weight management training program also identified a nonsignificant decrease in TC.72
Six AE studies reported outcomes for HDL-C.57–61, 63 While three reported no changes,57, 58, 60 one reported a statistically significant increase59 and two reported very small, nonsignificant increases (10 percent and 8 percent).61, 63 Four survey studies reported on HDL-C, with one identifying a significantly significant 14 percent decrease (p <0.05) for individuals who were physically active compared to those who were sedentary.69 Two others identified significant positive correlations (r = .46 and .63, p <0.05),13, 14 while another reported no correlation.71 Oddly, the weight management study reported a significant decrease in HDL-C.72 Measures for TC/HDL-C were similarly inconclusive. Of five AE studies, two reported no changes,57, 60 while three reported statistically significant reductions in values ranging from 18 percent to 23 percent.58, 61, 63 Two survey studies identified significant inverse correlations between physical activity and TC/HDL-C (r = -.49, p <0.05 for both),14, 70 one identified a significant reduction (p <0.05) among those who were physically active compared to sedentary,69 and one showed no correlation.71
In two of four AE studies reporting LDL-C measures, levels were significantly decreased by 15 percent and 25 percent (p = .05 for both);61, 63 no changes were observed in the others.57, 58 However, two of three survey studies identified significant inverse correlations between self-reported physical activity and LDL-C levels (r = -.28 and -.40, p = 0.003 and p <0.01 respectively).70, 71 The third survey study found no difference between groups.69 The weight management program was associated with a nonsignificant decrease.72
While one study identified a statistically significant 31 percent average decrease in TG among those assigned a high intensity AE training protocol,58 two others showed decreases that were nonsignificant,61, 63 and still two others found no change.59, 60 Among the four self-report surveys, one identified a nonsignificant 32 percent decrease among those who were physically active compared to sedentary.69 Three others identified no correlation between physical activity and TG levels.13, 70, 71
The study by Davies and McColl54 identified no association between physical activity levels and overall cardiovascular morbidity.
Evidence on effects of exercise on lipid and carbohydrate metabolism disorders is inconclusive. Studies to date have been short in duration, involved few subjects, and relied on study designs highly susceptible to error. Future collaborative research is needed to study both efficacy and effectiveness of such interventions in the population of individuals with SCI.
There were no prospective studies that evaluated dietary and/or lifestyle interventions on carbohydrate related outcomes.
Only two prospective studies that evaluated dietary and/or lifestyle interventions to reduce lipid levels were identified and met inclusion criteria.20, 72 No studies assessing pharmacologic interventions were identified. The two dietary/lifestyle case series studies included 238 subjects, overwhelmingly male (87 percent). Quality of the two studies was poor.
One controlled clinical trial compared the effect of a dietary intervention referral compared to no dietary referral over a mean of 16 months.20 Overall, mean age was 38.5 years and 89 percent were male. All subjects must have had an SCI of at least two years in duration. Group 1 (n=86) received a dietary intervention referral based on the recommendations of the American Heart Association and American Dietetic Association Guidelines. These subjects had a total cholesterol level greater than 200 mg/dL. Group 2 (n=136) received no dietary intervention referral. All subjects had a total cholesterol level ≤200 mg/dL. Group 1 subjects were significantly older (mean 42.8 versus 35.7, p <0.0001) and had a longer post-injury duration (15.6 versus 11.1 years, p <0.0001) compared to Group 2 subjects. Dietary intervention was effective in reducing some lipid parameters. There were significant reductions in total and low density lipoprotein cholesterol levels from baseline in Group 1, 234 to 224 (p <0.001) and 159 to 151 (p = 0.004), respectively. Levels increased slightly but not significantly in Group 2. In Group 1, 67 percent had decreases in LDL-C compared to 47 percent in Group 2 (p = 0.007). Secondary analysis found 15 percent had reductions ranging from 30 to 69 mg/dL and the LDL-C values declined from greater than 135 mg/dL to <135 mg/dL in 21 percent. There were no significant effects on high density lipoprotein cholesterol or triglyceride levels in either group.
The second uncontrolled pilot study evaluated a weight management program consisting of 12 classes for 12 weeks, primarily led by a registered dietician.72 Classes covered nutrition, exercise, and behavior modification. The dietary approach utilized a time-calorie displacement diet. The study followed 16 overweight subjects (BMI ≥25), up to 24 weeks. Subjects were on average 44 years of age, nine were men, 13 were White, and three were African American. There were no significant changes in total and LDL cholesterol levels from baseline at weeks 12 and 24. At week 12, TCl was reduced by 5.8 mg/dL (p = 0.28) and LDL cholesterol by 1.8 mg/dL (p = 0.76). By week 24, the mean changes were 0.3 mg/dL (p = 0.96) and -4.2 mg/dL (p = 0.42), respectively. HDL cholesterol was reduced significantly by 3.2 mg/dL from a baseline value of 43.1 mg/dL (p = 0.03) at week 12 and -0.9 mg/dL (p = 0.59) by week 24.
The present systematic review evaluated published evidence regarding the prevalence of lipid and carbohydrate disorders, CVDs, and mortality in adults with chronic posttraumatic SCI. We attempted to assess the contribution of risk of these disorders to CVD morbidity and mortality and whether they vary according to SCI status or compared to able-bodied individuals. The potential efficacy and harms of interventions to improve carbohydrate and lipid disorders in this population was also examined. This information was synthesized to determine if compared to able-bodied adults individuals with SCI:
have a different prevalence of carbohydrate disorders;
have increased risk of CVD morbidity and mortality,
have CVD and/or carbohydrate/lipid benefits from specific interventions;
should have thresholds/methods for detection or treatment modified.
The level of evidence addressing these issues is low. Most studies were retrospective, small, lacked adequate controls, and did not assess or adjust for confounding factors. Outcome measure definitions varied widely. However, limited low quality data suggest that adults with SCI are not at markedly higher risk of carbohydrate and lipid disorders or CVD than appropriately matched able-bodied individuals. Except for assessment of body composition/obesity, evidence does not support that diagnostic and treatment thresholds or methods for carbohydrate and lipid disorders should differ in SCI compared to able-bodied individuals. Assessment of insulin resistance and impaired glucose tolerance are not routinely performed in able-bodied individuals. The effectiveness of screening to improve clinical outcomes by detection of pre-diabetes (impaired fasting glucose or impaired glucose tolerance), insulin resistance, and diabetes in asymptomatic adults has not been demonstrated.73 Use of these tests is limited due to their inconvenience, complexity of testing requirements, costs, and current lack of accuracy. The OGTT is inconvenient and not ordered by most physicians to diagnose diabetes, even among those at risk. Additionally, about one-half with IGT or OGTT would have normal tests if repeated. Similar concerns exist with the criteria used to define impaired fasting glucose. Because the glucose concentration distribution is unimodal, the choice of cutpoints used to designate abnormalities of carbohydrate metabolism is arbitrary. Very little high quality data exist on the independent role of gender, race, disease severity, level, or duration. Any observed differences in prevalence or risk is relatively small in magnitude, inconsistent in direction according to study or risk characteristic, and/or could be confounded by differences in other known risk factors: age, smoking, exercise status, family history, etc.).
Assessment of obesity using BMI, is likely to be inaccurate and underestimate body fat assessment in adults with SCI. For other measures of carbohydrate and lipid abnormalities there is no high quality evidence to indicate that different thresholds (or biomarkers) should exist for SCI individuals compared to able-bodied adults to identify patient risk level, define disease status, or initiate treatment. Little data exist on the effects of interventions to improve carbohydrate and lipid abnormalities, including the effect of exercise.
Several previous reports and reviews have suggested that the prevalence of carbohydrate and lipid disorders, as well as cardiovascular morbidity and mortality, is much higher in adults with SCI compared to able-bodied individuals. However, the prevalence of insulin resistance, metabolic syndrome, diabetes mellitus, impaired glucose tolerance, dyslipidemia, and obesity in a population is highly dependent upon demographics of the population, including most importantly the age distribution, but also socioeconomic status and race/ethnicity. The dependence of these conditions on population characteristics makes it difficult to make between study comparisons, since the population characteristics vary greatly both between and within studies. These factors may explain the wide variation in study prevalence estimates as well as the relative risk compared to different able-bodied control populations. Additionally, definitions of disease or condition may also alter prevalence estimates. In the one included study assessing metabolic syndrome, the definitions used by the authors for hypertension, obesity, diabetes, and lipid disorders are not widely accepted or utilized in studies in able-bodied adults. Their definitions increase the estimated prevalence of disease in their population and relative to studies of able-bodied individuals that use established definitions.
Our findings of cardiovascular disease prevalence and mortality were lower than frequently reported. Previous reviews often incorporated a broad definition of CVD.76 Definitions included in these reports were hypertension, as well as self-reported signs and symptoms of leg swelling or palpitations.56 The clinical significance and the relation to CVD of leg swelling and palpitations are not clear. Accurate assessment of blood pressure in SCI individuals is problematic. No validated definitions or thresholds for hypertension interventions exist in SCI patients due to blood pressure measurement issues related to autonomic dysreflexia, muscle spasticity or hypotonicity, use of arms for wheelchair transportation, and, most importantly, the lack of long-term data correlating blood pressure and treatment with morbidity and mortality in SCI individuals. These highly prevalent conditions are much more common and inflate prevalence estimates of cardiovascular disease in SCI individuals but result in less morbidity than myocardial infarction or stroke. Use of self-reported disease classification or death certificates for cause of death may also result in biased estimates of disease prevalence or mortality. Several factors may contribute to the increased prevalence of undiagnosed CVD in SCI individuals, including access and quality of care, asymptomatic angina in patients with diabetes or upper level injury,77, 78 and metabolic syndrome, unstable blood pressure, and cardiac rhythm.79, 80 Screening to detect asymptomatic heart diseases, including coronary heart disease, arrhythmias, and autonomic dysreflexia, may result in higher prevalence of CVD in this population.
Prevalence of CVD in aging SCI individuals can be attributable to age rather than injury. Patients differed by the prevalence of risk factors prior to injury and by age at the time of injury, both could modify the association between SCI and CVD. Indeed, recently published retrospective analysis found that presence of cardiovascular disease prior to injury was associated with a 280 percent increase in risk of death (relative risk 2.8, 95 percent CI 1.22; 6.40).81 For each additional year of age at injury, the relative risk of dying was increased by 8 percent (RR 1.08, 95 percent CI 1.06; 1.09).81
Whether the reported increased risk of all CVD in tetraplegic compared to paraplegic individuals can be interpreted as an evidence of higher morbidity53, 76 requires additional studies. Limited evidence suggests that CVD may contribute to approximately 20 percent of all deaths in SCI patients1, 36, 49, 52 and coronary heart disease in 91–3 to 1381 percent of all deaths.1–3, 81 There is insufficient evidence to determine whether percentage of deaths due to CVD differs in SCI adults compared to appropriately matched able-bodied individuals. One study suggested that presence of heart diseases was associated with an increased risk of death by 3.7 fold in SCI patients independent of age and other risk factors.52 Limited evidence suggests that the contribution of different forms of heart disease (e.g., ischemic versus nonischemic coronary heart disease) to overall CVD mortality in SCI patients may differ from the general population.
CVD morbidity and mortality in SCI patients showed inconsistent differences compared to the general population. Survival rates in aging injured patients can depend on severity of CVD and quality of care. Whether the incidence of CVD was not well documented in the studies or the prognosis of CVD is worse in the SCI than in the able-bodied population is unclear. Case fatality from CVD in SCI patients compared to the general populations is not well established. However, some evidence suggested that case fatality rate for pneumonia was higher in injured than in the general population.109
The independent contribution of diabetes and impaired glucose tolerance on CVD prevalence in adults with versus without SCI has not been reported. The association between metabolic control and CVD in adults with SCI remains unclear. Vascular complications were not different in SCI users of the VA health care system who were diabetic compared to diabetic able-bodied veterans.37 The role of lipid disorders on CVD in SCI individuals is not well documented and needs future investigation.
Some potentially eligible studies that may be cited as evidence of altered risk were excluded due to small sample size that limited generalizability (n=45, number of SCI individuals in each study ranged from 1–77). These studies were also of low quality and relevance because they were from a single center, not from the United States, lacked controls, and/or did not assess clinically relevant carbohydrate and lipid disorders. The impact of these studies on our overall findings regarding carbohydrate, lipid and body composition disorder prevalence, and subsequent clinical decision making is likely to be small. Only 17 excluded studies had control groups. The largest study reporting glucose intolerance and insulin resistance in the United States lacked controls, was comprised of 57 adults from a single center, and was published in 1983. The largest excluded controlled study of lipid disorders was a single center report comprised of 60 young SCI adults (mean age = 28 years) and 28 age and gender matched healthy able-bodied controls. Serum LDL cholesterol was higher (109 mg/dL vs. 91 mg/dL; p = 0.04) and HDL cholesterol lower (33 mg/dL vs. 44 mg/dL; p = 0.004) in SCI adults versus controls. The authors concluded that “serum lipoprotein levels should not be ignored for the followup of the patients with spinal cord injury.”75 We agree with their conclusion. Other excluded studies were of even lower quality and relevance to health care in the United States because they were smaller, from a single center, not from the United States, lacked controls, and/or did not assess clinically relevant carbohydrate and lipid disorders.
The evidence that exercise programs alter carbohydrate and lipid outcomes is of poor quality and inconclusive. There were relatively few consistent findings pertaining to plasma glucose, two-hour post-load glucose, fasting insulin, or two-hour post-load insulin. Similarly, little consistency was reported between studies for HDL-C, TC/HDL, and TG. Results may have indicated some overall post-training benefits for outcomes of TC and LDL-C. While many reported findings appear to be encouraging and are suggested as such in the primary papers as well as past reviews,85, 110 caution is warranted when interpreting these studies. There was a general lack of quantity, quality, and consistency in methods and outcomes across studies. Overall, reports were based on short-term exercise protocols, often involved carefully recruited hospital- and/or clinic-based patients, and failed to consider implementation or sustainability of exercise interventions in community-based populations. Only one study examined the effects of exercise on coronary heart disease outcomes.54
The exercise described in these papers varied considerably from one study to the next. In the cross-sectional surveys,13, 14, 54, 69–71 parameters of physical activity were rarely reported. Generally, questions pertaining to amount of physical activity per week were asked.14, 69–71 In exercise intervention studies, little consistency in duration, mode, frequency, or intensity of the exercise programs existed. The length of the exercise protocols ranged from 8 to 52 weeks; most were only 8 to 16 weeks in duration.57–61, 64–67 These studies may not have been long enough to impart measurable physiological benefits to study participants. Further, the types of exercise, frequency of sessions, and intensity of exertion were also varied, making results about preferred forms of exercise inconclusive.
Patient populations and outcome measures were also highly inconsistent. Study designs consisted only of case series, involving small numbers of subjects in hospital or clinical settings, or the cross-sectional surveys. The total number of subjects participating was low (n=101 for carbohydrate studies and n=292 for lipid studies) and, for the most part, subjects were not randomly selected from broader patient or community populations. These methods are considered highly susceptible to bias. Subjects that participated in the case series studies were likely a highly-motivated group of individuals, nonrepresentative of the broader population of those with SCI. Little information was presented on those asked to participate but who chose to abstain. Further, the measures of self-reported exercise or physical activity utilized in the cross-sectional surveys likely led to misclassification through recall error and social desirability issues. Even if measurement of physical activity was accurate, the cross-sectional nature of these surveys leaves results highly questionable due to possible confounding. For example, those who did not exercise may have had underlying carbohydrate and/or lipid metabolism disorders. This would make physical activity positively correlated, but not necessarily causally associated, with better carbohydrate and lipid measures.
None of the intervention studies used improvement in glycated hemoglobin (A1C) as an outcome. The effect of exercise on blood glucose often is delayed for several hours. A1C reflects the integrated effect on blood glucose throughout the day and A1C is easy to measure. Therefore, it would likely be preferable for future studies to track A1C changes rather than transient and more difficult to measure insulin or glucose levels or areas under the insulin and glucose curves for a few hours.
Even if consistent, convincing data were generated from these types of studies, there is no evidence for subsequent, successful translation of exercise interventions to a lesser motivated or community-based SCI population. Effectiveness of exercise interventions has yet to be studied in a population of individuals with SCI. Implementation and sustainability of exercise in this population is likely to be more challenging than in an able-bodied population, given the environmental barriers and physical risks, such as exercise-induced autonomic dysfunction and musculoskeletal injury.8, 26 The risk of further, unperceived health problems, such as silent ischemia, in denervated subjects should be carefully considered prior to implementing exercise-related recommendations or policies.
Exercise and dietary programs among able-bodied individuals have demonstrated a modest improvement in carbohydrate and lipid parameters among selected highly motivated individuals. Translation of these findings to community settings of SCI adults has not been demonstrated, and even the effectiveness in the general able-bodied population is unclear. For example, a recent randomized trial evaluated the effects of 22 weeks of aerobic training, resistance training, or both (three times per week) on glycemic control in 251 able-bodied adults with Type 2 diabetes.86 Combined training resulted in a 1 percent absolute reduction in glycated hemoglobin values versus sedentary controls. Reductions due to either resistance or aerobic training alone were about one-half that seen with combination therapy. Their was no difference in lipid values, blood pressure, lean body mass, fat mass, or percent body fat of any of the exercise programs versus controls. Adverse events were more common in the exercise group, and 14 percent of those randomized to exercise dropped out.
Ultimately, higher-quality studies examining effects of exercise on the health of subjects with SCI need to be conducted. While carbohydrate and lipid metabolism measurements are important, intermediate measures, extending such studies into longer term outcomes such as diabetes mellitus, coronary heart disease, and survival are important. In addition, clinical and research questions pertaining to obesity in individuals with SCI remain to be answered. The most appropriate measurements and definition of obesity for those with SCI have not been identified at this time. To continue the use of BMI as a measurement of obesity, it must be assessed whether current BMI cutpoints for the general population can be extrapolated to those with SCI, or whether cutpoints need to be specific to this population, considering both SCI type and level.
Little information exists regarding the impact of dietary or pharmacologic interventions on adults with SCI. Recommendations currently exist for disease definitions for diabetes and lipid abnormalities in able-bodied adults. Several large RCTs have established the effectiveness of statins used for primary prevention in able-bodied adults with mean baseline LDL cholesterol of approximately 150 mg/dL. Many of these individuals had other competing risks such as hypertension and cigarette use. Use of statins in able-bodied adults with diabetes have been demonstrated to be effective even if baseline LDL-C is less than 130 mg/dL. The mean baseline LDL-C in populations of SCI individuals included in this review was 125 mg/dl. Effectiveness and harms associated with statins may differ in SCI individuals compared to able-bodied adults. However, unless contrary data exist, it seems reasonable to extrapolate these findings and recommendations for similar pharmacologic intervention thresholds for treatment of lipid abnormalities in SCI individuals as used in able-bodied adults. There have been no primary prevention studies among individuals with low HDL-C. Recent studies of treatments to raise HDL-C have been stopped due to harm. Existing recommendations to assess cardiovascular risk for able-bodied individuals suggest that all adults should have a complete lipid profile, including HDL and LDL cholesterol levels, as well as family history, smoking status, and gender. The treatment recommendations should be based on that comprehensive risk assessment. Future studies are needed to determine if SCI should be included as an independent risk factor.
With regard to interventions to prevent and treat diabetes, currently no large scale randomized trials have demonstrated that aggressive control of Type 2 diabetes reduces cardiovascular complications. A recent systematic review assessed the comparative effectiveness and safety of oral medications for Type 2 diabetes mellitus. The authors reported that there was no definitive evidence about the comparative effectiveness of oral diabetes agents on all-cause mortality, cardiovascular mortality or morbidity, peripheral arterial disease, neuropathy, retinopathy, or nephropathy.82 Two more recent meta-analyses of thiazolidinediones have been conducted. Among able-bodied patients with impaired glucose tolerance or Type 2 diabetes (n=14,291), rosiglitazone use for at least 12 months was associated with an increased risk of myocardial infarction and heart failure. There was no difference in increase risk in cardiovascular mortality.83 A review of pioglitazone (n=16,390) showed a significantly lower risk of death myocardial infarction or stroke among patients with Type 2 diabetes and inadequately glycemic control. Serious heart failure was increased.84 Unless future RCTs demonstrate evidence to the contrary, a reasonable policy would be to implement existing diabetes detection and management guidelines used for able-bodied adults.
Available evidence regarding the prevalence, impact, and outcomes of carbohydrate and lipid disorders in adults with chronic SCI is weak. Evidence is limited by relatively few studies, small sample size, lack of appropriate control groups, failure to adjust for known confounding variables, and variation in reported outcomes. However, the existing evidence does not indicate that adults with SCI are at markedly greater risk for carbohydrate and lipid disorders or subsequent cardiovascular sequelae than able-bodied adults. Cardiovascular diseases are among the leading causes of death in aging patients with chronic SCI. Therefore, patients with SCI should be assessed and treated according to existing guidelines for able-bodied individuals to reduce cardiac morbidity and mortality in this population associated with carbohydrate and lipid disorders.
BMI to assess obesity and body composition is likely inaccurate and underestimates fat mass in adults with SCI. Available evidence does not support establishing different thresholds to define and treat abnormal traditional lipid and carbohydrate measures or to utilize other markers (e.g., insulin sensitivity or impaired glucose tolerance) for SCI individuals compared to able-bodied adults. Because evidence is weak, it is not possible to conclude that an increased risk of these disorders and their subsequent cardiovascular sequelae do not exist or that use of alternative measures of abnormality may not someday be found beneficial.
Individuals with SCI may have unique physiologic differences compared to able-bodied individuals. Therefore, caution is advised in attempting to extrapolate findings from studies conducted in able-bodied adults evaluating efficacy and harms of interventions to improve carbohydrate, lipid disorders and subsequent coronary vascular disease.
If clinical uncertainty regarding carbohydrate and lipid disorder risks in adults with SCI and determining the most appropriate interventions remain high priority areas, then future high quality research is needed. Until that time, a reasonable policy would be to use similar criteria to identify and treat carbohydrate and lipid disorders (outside of body composition assessment) in adults with SCI as currently recommended for able-bodied adults. The role of exercise in SCI individuals also represents a unique challenge and requires further exploration into the benefits, risks, and potential implications of broader based exercise programs. This systematic review did not assess the diagnosis and treatment of hypertension in SCI individuals or the other potential benefits of diagnosis and management of SCI individuals, such as improved wound healing. Additional clinical and research activities are needed to address these issues.
A major gap in the evidence is the lack of high-quality prospective epidemiologic studies assessing the prevalence and impact of lipid and carbohydrate abnormalities and corresponding CVD complications in SCI individuals, especially compared to appropriately matched able-bodied controls. Future research could include a large prospective multicenter cohort study of adults with SCI. Risk assessment should be started at the time of injury and continued during long-term followup. Prevalence and incidence assessment needs to be objective rather than self reported. Inclusion of baseline and followup physiologic and serologic values (e.g., body composition measures, actual lipid and carbohydrate laboratory values) and standardized outcomes are made according to well-recognized diagnostic criteria of heart diseases. Expansion of existing cohort studies in the VA, a large non-VA cohort study, and future RCTs that aim to test whether more aggressive screening or treatment within SCI populations actually reduces disease prevalence, morbidity, and mortality could be initiated. Additional information on women is needed.
To a large extent, research within the VHA patient population has provided an important foundation to the current knowledge, particularly within the United States, regarding the prevalence of carbohydrate and lipid disorders and relevant considerations in persons with SCI. If there is continued concern that adults with chronic SCI have a different prevalence than adults without SCI, then future research would benefit from an expansion of the existing cohort studies in the VA, a large non-VA cohort study, and future RCTs that aim to test whether more aggressive screening or treatment within SCI populations actually reduces disease prevalence, morbidity, and mortality.
The VA administrative and clinical datasets and data from other large health care systems provide researchers with a wealth of information regarding the epidemiology of carbohydrate and lipid disorders with SCI patients. These datasets allow for rapid estimation of the magnitude of disease burden from carbohydrate and lipid disorders and can help to develop hypotheses about the role SCI may play in the development of disease. However, administrative datasets often suffer from selection bias in terms of the persons included and the measurements obtained. Therefore, such datasets need to be enriched with prospective cohort style data collection. This can be accomplished by designing a registry of adults with SCI and collecting a baseline battery of key measurements on all persons. This comprehensive set of baseline measurements can then be combined with standard outcomes data collected in these healthcare settings to provide a detailed description of the natural history and etiology of various diseases.
While in many ways the VHA provides an ideal U.S. setting to obtain important information on persons with SCI, it must be accompanied by complementary research on representative SCI persons from health systems outside of the VA. This is particularly important, since women are currently underrepresented in VHA datasets, and veterans have often been found to have more competing comorbidities than nonveteran populations,37 which can make generalizations difficult without complementary non-VA data. Additionally, current reports indicate that approximately 90 percent of SCI subjects were men. It is not known if this is representative of the U.S. SCI population or only those reporting this information.
RCTs will be needed to further extend the information obtained from future prospective observational studies. Regardless of whether or not future trials indicate that individuals with SCI are at an increased risk of carbohydrate and/or lipid disorders, it is clear that, like the general population, a significant number of SCI individuals do have carbohydrate and lipid disorders and techniques for treating these disorders may need to be modified to meet the specific needs of those with SCI to ensure that they are being most appropriately treated. RCTs will therefore be needed to compare the effectiveness of any such modifications in treatment technique and intensity, including the same pharmacological agents recommended for the general population and specific for SCI patients' treatment options that would target impaired glucose tolerance and insulin sensitivity.
If prospective cohort studies identify an increased risk in adults with SCI, RCTs will be needed to further extend the information. Techniques for identifying and treating these carbohydrate and lipid disorders and CVDs may need to be modified to meet the specific needs of those with SCI. In addition, continued clinical and research questions pertaining to obesity in individuals with SCI remain to be answered. These include identification of the most appropriate measurements and definition of obesity for those with SCI, and whether current BMI cutpoints for the general population can be validly extrapolated to those with SCI.
RCTs evaluating the potential effectiveness and harms of interventions to alter CVD risk factors and reduce CVD incidence, morbidity, and mortality are needed. The level of injury, neurological impairment, and other known or potential confounders including smoking status, hypertension, family history, race, age, diabetes, infections including, socioeconomic status, and quality of health care should be analyzed as possible effect modifiers of the association between well-known risk factors and cardiovascular morbidity and mortality.
Given the variation in design across studies, the lack of consistent findings in this review was not surprising. While improved studies will be challenging due to limited resources, complicated study questions, a relatively small subject population, and invasive intervention, policy recommendations cannot be generated until higher quality evidence is available. Consistent, higher quality research on exercise and metabolic and cardiovascular health in SCI patients is needed. Studies examining efficacy as well as effectiveness of exercise interventions are needed.
Continued research should be conducted to gain a better idea of the important barriers to exercise experienced by individuals with SCI and to develop novel methods to overcome these barriers. Preliminary studies may also assess which patients are most in need of intervention, the best types of exercise programs and equipment, and how to modify them based on characteristics of the injury. For example, telemedicine approaches to home-based exercise programs could potentially help overcome barriers to accessing traditional facilities or equipment. Whether qualitative or quantitative, this preliminary work would not only inform the development of exercise programs but also the research used to evaluate efficacy and effectiveness.
Accomplishing the level of research needed will likely require a collaboration of researchers across sites. Convening a consortium of experts is a practical first step. Cooperative research groups could determine the most appropriate and pragmatic study parameters, including intervention type and outcome measures, and could propose the most feasible quality studies. RCTs and prospective epidemiologic studies for individuals with SCI could both contribute enhanced knowledge to the current evidence base. While such studies are resource intensive, these accomplishments could perhaps be better achieved through the pooling of resources, either by funding agencies, or by researchers through multiple site collaborations. The VA medical system, the SCI model systems sites, or the National SCI Statistical Center at the University of Alabama Birmingham may be poised to lead such multi-site collaboration and studies.
Short-term, intermediate outcomes of exercise, as were typically reported in the current studies, may not be ideal or definitive measurements for this type of research. Studies ideally would focus on long-term clinically relevant outcomes such as prevention of diabetes mellitus, coronary heart disease, and mortality.
An RCT would provide the best evidence for or against the use of exercise to prevent or control carbohydrate and lipid disorders among those with SCI, though conducting adequately sized studies would be difficult and would require cooperative group participation. Studies on exercise and metabolic and cardiovascular outcomes in the SCI population will be more definitive if important demographic and injury parameters are considered. Key variables that should be included in future studies are patient age, race, and gender; comorbid conditions; baseline lipid and carbohydrate related measures; duration, level, and completeness of SCI; functional status; baseline physical activity; exercise program type, frequency, intensity, and duration; and life satisfaction and other important psychosocial variables. RCTs and prospective epidemiologic studies with adequate numbers of participants should provide the least confounded evidence for or against exercise programs if the intervention and control groups are appropriately balanced and/or stratified by these variables.
Further research will be needed to translate any findings of exercise efficacy into effective community-based interventions. Even if efficacy is promising, it will remain to be seen if these interventions are feasible in a community setting, and if the interventions, as well as health outcomes, are sustainable over time. Further evidence on how best to motivate individuals to sustain exercise, while preventing and identifying potential harms, will be needed.
RCTs evaluating the potential effectiveness and harms of pharmacologic and dietary interventions to alter CVD risk factors (diabetes, lipid abnormalities, and/or obesity) and reduce CVD incidence, morbidity, and mortality may be needed if there is continued concern that results may differ in SCI populations compared to able-bodied adults.
| AB | Able bodied |
| AE | Active exercise |
| AHRQ | Agency for Healthcare Research and Quality |
| BMI | Body mass index |
| C | Cholesterol |
| CDC | Centers for Disease Control |
| CI | Confidence interval |
| CVD | Cardiovascular disease |
| DXA | Dual energy x-ray absorptiometry |
| ECG | Electrocardiogram |
| EPC | Evidence-based Practice Center |
| FES | Functional electrical stimulation |
| HDL | High-density lipoprotein |
| HI | High intensity |
| HRR | Heart rate reserve |
| ICD | International classification of diseases |
| IGT | Impaired glucose tolerance |
| LBBB | Left bundle branch blocks |
| LDL | Low-density lipoprotein |
| LI | Low intensity |
| LVH | Left ventricular hypertrophy |
| MET | Metabolic equivalents |
| N | Number |
| NA | Not applicable |
| OGTT | Oral glucose tolerance test |
| OR | Odds ratio |
| PE | Passive exercise |
| RCT | Randomized controlled trial |
| SCI | Spinal cord injury |
| TC | Total cholesterol |
| TEP | Technical expert panel |
| TG | Triglycerides |
| VA | Veterans Affairs |
| VHA | Veterans Health Administration |
| WAFT | Wheelchair aerobic fitness trainer |
| WMD | Weighted mean difference |
| TEP Member | Affiliation |
|---|---|
| Yuying Chen, MD, PhD | Physical Medicine and Rehabilitation |
| University of Alabama at Birmingham | |
| David R. Gater, Jr, PhD, MD | Department of Veterans Affairs |
| Hunter Holmes McGuire Medical Center | |
| Leonard Pogach, MD | Department of Veterans Affairs |
| New Jersey Health Care System | |
| Suparna Rajan, PhD, RD | Department of Veterans Affairs |
| Puget Sound Health Care System |
| Medical Subject Headings Terms and Key Words | Number of Retrieved References |
|---|---|
| “Spinal Cord Injuries” [MeSH] AND (“Cardiovascular Diseases” [MeSH] OR “Cardiology” [MeSH]) NOT review NOT letter NOT editorial NOT Case Reports | |
Limits: All Adult: 19+ years, Entrez Date from 1990/01/01 to 2007/07/01, English, Humans | 233 |
| “Spinal Cord Injuries” [MeSH] AND Cardiovascular Diseases | |
Limits: English, Humans | 1,467 |
| “Spinal Cord Injuries” [MeSH] AND Cardiovascular Diseases | |
Limits: English, Randomized Controlled Trial, Humans | 20 |
| “Spinal Cord Injuries” [MeSH] AND Cardiovascular Diseases | |
Limits: English, Clinical Trial, Humans | 55 |
| “Spinal Cord Injuries” [MeSH] AND “Cardiovascular Diseases” [MeSH] | |
Limits: English, Clinical Trial, Humans | 55 |
| “Spinal Cord Injuries” [MeSH] AND “Cardiovascular Diseases” [MeSH] | |
Limits: English, Randomized Controlled Trial, Humans | 20 |
| “Spinal Cord Injuries” [MeSH] AND “Cardiovascular Diseases” [MeSH] | |
Limits: English, Meta-Analysis, Humans | 1 |
| “Spinal Cord Injuries” [MeSH] AND “Cardiovascular Diseases” [MeSH] | |
Limits: English, Humans | 1,464 |
| “Spinal Cord Injuries” [MeSH] AND “Cardiovascular Diseases” [MeSH] AND “Insulin Resistance” [MeSH] | |
Limits: English, Humans | 2 |
| “Cardiovascular Diseases” [MeSH] Limits: English, Humans | 780,975 |
(“Cardiovascular Diseases” [MeSH] OR “Cardiology” [MeSH]) NOT review NOT letter NOT editorial | |
Limits: Adult: 19–44 years, Middle Aged: 45–64 years, Middle Aged + Aged: 45+ years, Aged: 65+ years, 80 and over: 80+ years, English, Humans | 402,080 |
(“Cardiovascular Diseases” [MeSH] OR “Cardiology” [MeSH]) | |
Limits: Adult: 19–44 years, Middle Aged: 45–64 years, Middle Aged + Aged: 45+ years, Aged: 65+ years, 80 and over: 80+ years, English, Humans | 456,995 |
“Spinal Cord Injuries” [MeSH] NOT review NOT Letter NOT editorial AND “Diabetes Complications” [MeSH] NOT review NOT letter NOT editorial | |
Limits: Adult: 19–44 years, Middle Aged: 45–64 years, Middle Aged + Aged: 45+ years, Aged: 65+ years, 80 and over: 80+ years, English, Humans | 19 |
“Trauma, Nervous System” [MeSH] AND (“Spinal Cord” [MeSH] OR “Spinal Cord Injuries” [MeSH] OR “Spinal Cord Diseases” [MeSH]) NOT review NOT letter NOT editorial AND (“Cardiovascular Diseases” [MeSH] OR “Cardiology” [MeSH]) | |
Limits: Adult: 19–44 years, Middle Aged: 45–64 years, Middle Aged + Aged: 45+ years, Aged: 65+ years, 80 and over: 80+ years, English, Humans | 669 |
“Autonomic Dysreflexia” [MeSH] AND (“Cardiovascular Diseases” [MeSH]) NOT review NOT letter NOT editorial | |
Limits: Adult: 19–44 years, Middle Aged: 45–64 years, Middle Aged + Aged: 45+ years, Aged: 65+ years, 80 and over: 80+ years, English, Humans | 17 |
“Autonomic Dysreflexia” [MeSH] AND (“Cardiovascular Diseases” [MeSH]) | |
Limits: Adult: 19–44 years, Middle Aged: 45–64 years, Middle Aged + Aged: 45+ years, Aged: 65+ years, 80 and over: 80+ years, English, Humans | 23 |
“Brown-Sequard Syndrome” [MeSH] AND (“Cardiology” [MeSH]) | |
Limits: Adult: 19–44 years, Middle Aged: 45–64 years, Middle Aged + Aged: 45+ years, Aged: 65+ years, 80 and over: 80+ years, English, Humans | 0 |
“Brown-Sequard Syndrome” [MeSH] AND (“Cardiovascular Diseases” [MeSH]) | |
Limits: Adult: 19–44 years, Middle Aged: 45–64 years, Middle Aged + Aged: 45+ years, Aged: 65+ years, 80 and over: 80+ years, English, Humans | 8 |
“Quadriplegia” [MeSH] NOT review NOT letter NOT editorial AND (“Cardiovascular Diseases” [MeSH] OR “Cardiology” [MeSH]) | |
Limits: Adult: 19–44 years, Middle Aged: 45–64 years, Middle Aged + Aged: 45+ years, Aged: 65+ years, 80 and over: 80+ years, English, Humans | 299 |
“Paraplegia” [MeSH] NOT review NOT letter NOT editorial AND (“Cardiovascular Diseases” [MeSH] OR “Cardiology” [MeSH]) | |
Limits: Adult: 19–44 years, Middle Aged: 45–64 years, Middle Aged + Aged: 45+ years, Aged: 65+ years, 80 and over: 80+ years, English, Humans | 587 |
“Spinal cord injury” AND (“Cardiovascular Diseases/epidemiology” [MeSH] OR “Cardiovascular Diseases/etiology” [MeSH] OR “Cardiovascular Diseases/prevention and control” [MeSH]) NOT review Not letter Not editorial | |
Limits: Adult: 19–44 years, Middle Aged: 45–64 years, Middle Aged + Aged: 45+ years, Aged: 65+ years, 80 and over: 80+ years, English, Humans | 259 |
| Related Articles for PubMed (Select 16823238) | 302 |
| Select 3 document(s) | 3 |
| Search “Cardiovascular Diseases” [MeSH] AND “Spinal Cord Diseases” [MeSH] NOT review NOT case report NOT letter NOT editorial | |
Limits: All Adult: 19+ years, English, published in the last 10 years, Humans | 288 |
| Search “Cardiovascular Diseases” [MeSH] AND “Spinal Cord Diseases” [MeSH] NOT review NOT case report NOT letter NOT editorial | |
Limits: All Adult: 19+ years, English, Humans | 888 |
| Search “Cardiovascular Diseases” [MeSH] AND “Spinal Cord Diseases” [MeSH] NOT review NOT case report NOT letter NOT editorial | |
Limits: All Adult: 19+ years, Humans | 1,320 |
| Search “Cardiovascular Diseases” [MeSH] AND “Spinal Cord Diseases” [MeSH] | |
Limits: All Adult: 19+ years, Humans | 3,040 |
| Search “Cardiovascular Diseases” [MeSH] AND “Spinal Cord Diseases” [MeSH] | 5,414 |
| Search “Cardiovascular Diseases” [MeSH] | 1,366,747 |
| Search “Spinal Cord Diseases” [MeSH] | 71,345 |
- ID of the study from PubMed or Cochrane ____________
- Number of the study _______________
- First author _____________
- Year of the publication____________
- Design of the study:
- Observational prospective
- Observational retrospective
- Case-control
Level of evidence:
Description of the target population ______________________
Description and clear definition of primary outcomes_________________
Description and clear definition of secondary outcomes__________________
Validation of the measurements of the exposure_________________
Validation of the measurements of the outcomes___________________
Process of the subject selection_______________
Adequacy of the sampling (random selection or not)_______________
Assessment of selection bias____________________
Loss of followup_________________________
Length of followup (when applicable) in months_______________
Validity of the measurements of confounding factors_________________
Appropriateness matching________________________
Appropriateness of adjustment____________________
Appropriateness of standardization_____________________
Measurement of possible effect measure modification________________
External validity of the study____________________
Years of observation, interval______________________
Number of patients selected_________________________
Number of patients analyzed________________________
Data used in the analysis____________________
Adjustment for age of the patients, years________________
Adjustment for race of the patients_______________________
Adjustment for functional status, level of injury____________________
Adjustment for socioeconomic status of the patients_________________
Adjustment for comorbidities of the patients_________________
Patient age____________________
Patient race, % of blacks________________________
Patient gender, % of females_____________________
Time after injury in years_____________________
Diagnosis of insulin resistance and diagnostic criteria of insulin resistance________
Diagnosis of metabolic syndrome__________________
Diagnosis of diabetes mellitus ______________________
Diagnosis of impaired glucose tolerance____________________
% with insulin resistance__________________
% with metabolic syndrome__________________
% with diabetes mellitus_______________________
% with glucose tolerance______________________
% with elevated cholesterol_______________________
% with elevated LDL_______________________
% with elevated TG_____________________
% with decreased HDL____________________
% with dyslipidemia_________________________
% with obesity___________________________
% with abdominal obesity_________________
Diagnosis of hypertension___________________
Proportion of fat in total body mass__________________
Proportion of abdominal fat in total body fat_____________
Waist-hip ratio________________
% of subjects with I class of obesity_________________
% of subjects with II class of obesity___________________
% of subjects with III class of obesity_________________________
Proportion of patients in the sample with upper cervical SCI______________
Proportion of patients in the sample with low cervical SCI_______________
Proportion of patients in the sample with upper thoracic SCI_____________
Proportion of patients in the sample with lower thoracic SCI_________________
Proportion of patients in the sample with lumbar SCI______________________
Proportion of patients in the sample with sacral SCI____________________
Proportion of patients in the sample with coccygeal SCI________________
Proportion of patients in the sample with tetraplegia _________________
Proportion of patients in the sample with paraplegia __________________
Functional status of the patients (definition and level)___________________
Incidence of arrhythmia, events/year in 1,000 patients with SCI___________
% of patients with SCI with arrhythmia_____________________
Incidence of heart arrest, events/year in 1,000 patients with SCI____________
% of patients with SCI with heart arrest___________________________
Incidence of congestive heart failure, events/year in 1,000 patients with SCI_______
% of patients with SCI with congestive heart failure_____________________
Incidence of coronary disease, events/year in 1,000 patients with SCI___________
% of patients with SCI with coronary disease______________________
Incidence of stroke, events/year in 1,000 patients with SCI________________
% of patients with SCI with stroke_____________________
Incidence of hypertension, events/year in 1,000 patients with SCI___________
% of patients with SCI with hypertension________________________
Incidence of chronic renal failure, events/year in 1,000 patients with SCI________
% of patients with SCI with chronic renal failure_____________________
Mean of glomerular filtration rate in ml per min_______________________
Mortality, all causes, events/year in 1,000 patients with SCI______________
% of patients with SCI who died within year of followup_______________
Cardiovascular mortality, events/year in 1,000 patients with SCI_________
% of patients with SCI who died from CVD events within year of followup_______
Relative risk of arrhythmia, 95% CI__________________
Relative risk of arrest, 95% CI_____________________
Relative risk of CHF, 95% CI_______________________
Relative risk of coronary heart disease, 95% CI_________________
Relative risk of stroke, 95% CI______________________
Relative risk of hypertension, 95% CI___________________
Relative risk of CFR, 95% CI_________________________
Relative risk of all cause mortality, 95% CI____________________
Relative risk of CVD mortality, 95% CI______________________
Number of patients with arrhythmia ________________________
Number of patients with cardiac arrest________________________
Number of patients with congestive heart failure__________________
Number of patients with coronary heart disease_____________________
Number of patients with stroke___________________________
Number of patients with hypertension_______________________
Number of patients who died from CVD______________________
Free Full text in PMC]
Free Full text in PMC]
Free Full text in PMC]
Free Full text in PMC]
Free Full text in PMC]
Free Full text in PMC]
Free Full text in PMC]
Free Full text in PMC]
Free Full text in PMC]
Free Full text in PMC]
Free Full text in PMC]
Free Full text in PMC]
Free Full text in PMC]
Free Full text in PMC]
Free Full text in PMC]